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STELLINGEN 
1. De conclusie van Van Esch et al., dat "voor een schadelijk effect 
van sterk reactieve intermediairen van furazolidon niet gevreesd 
behoeft te worden", is voorbarig gezien net reversibele karakter van 
de covalente binding aan eiwit van het reactieve acryloni.tril derivaat 
in vitro. 
- G.J. van Esch, C.A. van der Heijden, B. van Klingeren en 
C.E. Voogd, Rijksinstituut voor de Volksgezondheid, Bilthoven, 
rapportnr. 358301001, 1983. 
- Dlt proefschrlft. 
2. De suggestie van Mattammal et al., dat het N-hydroxyderivaat van de 
nitrofuraan N-[4-(5-nitro-2-furyl)-2-thiazolyl]acetamide verantwoor-
delijk is voor de Interactie met glutathion, houdt geen rekening 
met een eventuele vorming van het reactieve acrylonitrilprodukt uit 
dit derivaat. 
- M.B. Mattammal, T.V. Zenser, M.O. Palmier and B.B. Davis, 
Cancer Research, 45 (1985) 149-156. 
- Dit proefschrift. 
3. Het "surface walks" mechanisme voor de conjugatiereacties gecata-
lyseerd door glutathion-S-transferases kan niet als algemeen worden 
aanvaard omdat van de meeste iso-enzymen bekend is dat deze niet, 
de voor dit mechanisme benodigde, vier cysteine residuen bevatten. 
- R.E. RidgewelJ and M.M. Abdel-Monem, Drug Metabolism and Disposition, 
15 (1987) 82-90. 
- C.B. Pickett, C.A. Telakowski-Hopkins, G.J.F. Ding and V.D.H. Ding, 
Xenobiotica, 17 (1987) 317-323. 
4. Gezien het feit dat verschillen in biotransformatie en toxische 
effecten tussen enantiomeren inmiddels goed gedocumenteerd zijn, 
moet het onaanvaardbaar worden geacht dat grote aantallen blolo-
gisch actieve verbindingen zoals pesticiden nog steeds op de markt 
worden gebracht als racemisch mengsel. 
- E.J. Ari'ens, in: Stereochemistry and Biological Activity of 
Drugs, E.J. Ari'ens et al. (eds). Blackwell Sci. Publ., Oxford, 
1983, p. 11-32. 
- Stereoselectivity in pesticide action, a notable source of 
problems, E.J. Ari'ens, J.J.S. van Rensen and W. Welling (eds), 
Elsevier/North-Holland, Amsterdam, in press. 
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PART I INTRODUCTION 
CHAPTER 1: In t roduc t ion 
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INTRODUCTION 
1. General Introduction 
During the last decennia considerable intensification has taken place 
in the Netherlands in animal husbandry in terms of total number of 
animals involved and of the number of animals raised per farm. For 
instance since 1960 a twentyfold increase of the number of swine per 
farm has been registered in the Netherlands (Table 1). 
Table 1: Numbers of food-producing animals in the Netherlands. 
Species 1960 1970 1983 1986 
cattle (x 103) 
cattle/farm 
swine (x 10^) 
swine/farm 
laying hens (x 10&) 
slaughter chickens (x 106) 
According to the Dutch Central Office for Statistics (CBS), Voorburg 
(Meitellingen) 
This development appeared to have consequences for the conditions of 
the animals, for instance abnormal behaviour was observed in swine 
such as tail-biting and cannibalism (Van Putten, 1968). Swine also 
became more susceptible to stress. Eikelenboom (1972) reported an 
increased incidence of death animals occurring during transport to the 
slaughterhouse and a pale, soft and exudative quality of the meat of 
these pigs. Furthermore the chance of outbreak of infectious diseases 
increased. Several measures had to be taken to either cure or prevent 
these anomalies. Abnormal behaviour was cured by improving the housing 
conditions with regard to factors like ambient temperature, humidity 
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and the availability of fresh straw. Stress was in the beginning 
treated by the application of tranquillizers but in recent years the 
selection of stress resistant strains has been emphasized. For the 
control and prevention of infectious diseases both the prophylactic 
and therapeutic use of veterinary drugs increased markedly. Especially 
administration of drugs via feed and drinkingwater has become common 
practice since the last two decades with the result that large numbers 
of animals are treated during most of their life-time with veterinary 
drugs. It should be noticed that relatively little attention has been 
payed to the prevention of these diseases through efforts to improve 
the hygienic conditions under which animals are housed. 
The number of available veterinary drugs increased. Hundreds of drugs 
are presently on the market and the number of formulations runs into 
the thousands. As most of these has not yet been adequately registered, 
it is virtually impossible to give an accurate overview of all veteri-
nary drug preparations. The top five compounds used for mass medica-
tion of swine and poultry through the feed include oxytetracycline, 
furazolidone, sulfadimidine, lincomycin and spectinomycin (Table 2). 
Table 2: Production of medicated feed (x 1000 kg) for swine and 
poultry in the Netherlands in 1985. 
Drug Swine Poultry 
Oxytetracycline 
Chlortetracycline 
Furazolidone 
Oxytetracycline/Furazolidone 
Sulfadimidine 
Lincomycin/Spectinomycin 
Amprolium 
51,099 
-
8,152 
1,267 
13,134 
18,952 
-
4,601 
3,676 
11,925 
1,750 
214 
334 
3,653 
Data represent 62.5% of total production in the Netherlands. 
Data from an internal annual report of the Dutch Commodity Board for 
Feeding Stuffs, The Hague. 
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The large use of veterinary drugs through mass medication poses a 
number of risks. First, pathogenic microorganisms may become resistant. 
Secondly, long term exposure to these compounds and/or its metabolites 
represent a health hazard for the animals concerned as well as for the 
human consumer of edible tissues originating from animals treated with 
veterinary drugs through the possible presence of residues. Conse-
quently, in various countries laws and regulations have been adopted 
in order to assure the good veterinary use of drugs and the consumer 
safety of food products from treated animals. In the Netherlands such 
a law, based on the EEC-guidelines 81/851 and 81/852 (Anonymous, 1981 
a,b) has become effective by the first of May 1986. For registration 
of drugs intended for mass medication of food producing animals, data 
have to be submitted concerning analytical, toxicological and pharma-
cological tests as well as results of clinical trials. As many drugs 
were already in use and quite a few of them not protected by patents 
anymore at the time the legal system was enforced, information of such 
compounds did not meet the new legal requirements. A typical example 
is the antimicrobial drug furazolidone, which is widely used in 
veterinary practice and of which essential information on metabolism 
and residu behaviour was lacking at the time the present study was 
started. The objective of the present investigation was to obtain a 
better understanding of the elimination kinetics and the biotransfor-
mation of furazolidone in swine, in relation to the safety of veteri-
nary residues. 
2. Furazolidone 
2.1 General properties 
Furazolidone [N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone (see 
Figure 1) belongs to the group of the 5-nitrofurans. 
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Figure 1: Chemical structure of furazolidone. 
Nitrofurans are synthetic products which are used worldwide for a 
variety of purposes. The first 5-nitrofuran synthesized was 5-nitro-
2-furaldehyde (Gilman and Wright, 1930) followed by other ones (Bryan, 
1978). The antimicrobial properties of the 5-nitrofurans have been 
described for the first time by Dodd and Stillman (1944), who 
discovered nitrofurazone, which was widely used in World War 11 as a 
antimicrobial drug against wound infections. 
One of the nitrofurans which became relatively popular was furazolidone. 
The pure compound is a yellow, crystalline solid with a molecular 
weight of 225, exhibiting absorption maxima at 259 nm and 367 nm; the 
aqueous solubility is limited (40 mg/1) and independent of pH (Paul 
and Paul, 1964). The drug is however readily soluble in dimethyl-
formamide or acetonitrile: 8.30 mg/ml and 3.75 mg/ml respectively 
(Cohen, 1979). In solution furazolidone is unstable under the 
influence of light (Kalim, 1985). Furazolidone displays a wide 
spectrum of antimicrobial activity both in vitro and in vivo (Yurchenko 
et al., 1953; Rogers et al, 1956; Paul and Paul, 1964), which was 
believed to be attributable to metabolic activation of the 5-nitro 
moiety of the furan ring (Dodd and Stillman, 1944; Dodd et al., 1950; 
Paul and Paul, 1964). The susceptibility of a number of micro-
organisms for furazolidone is shown in Table 3. 
The growth of most of these bacteria is inhibited in a concentration 
range of approximately 1-10 ug/ml, although for Proteus and Pseudomonas 
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much higher concentrations are needed. The difference in susceptibility 
of a species as reported by different authors may be explained by the 
absence of standardized determination methods. 
Furazolidone has been widely used for 30 years for the effective and 
specific treatment of bacterial or protozoal diarrhoea and enteritis 
caused by susceptible organisms (Phillips and Halley, 1986). The 
therapeutic use of furazolidone in man has been banned since 1980 in 
the Netherlands because of carcinogenic properties of the compound 
(Van Loenen, 1981). 
Furazolidone is approved in the Netherlands for the treatment of 
intestinal infections caused by E.coli in swine (300 mg/kg of feed) 
and for the treatments of intestinal infections caused by entero"-
bacteriaecae and bronchial infections in poultry except laying hens 
(200 mg/kg of feed) (Landbouwkwaliteitsbesluit Gemedicineerd Voeder, 
1975). 
Furazolidone may improve growth and feed conversion in amounts of 
25-220 mg per kg of feed (Clawspn and Alsmeyer, 1973; Czarnecki et 
al., 1974; Villadelgado and Lasanas, 1975; Wahlstrom and Libal, 1975; 
Balayut and Tibay, 1976; Karunajeewa, 1978). In the EC the use of 
furazolidone for growth promoting purposes in swine is not allowed. 
2.2 Toxicity 
2.2.1 General 
A well documented toxic action of furazolidone is its ability to 
inhibit the enzyme monoamine oxidase (MAO). This enzyme is involved 
in the metabolism of the neurotransmitter noradrenaline (Grobecker et 
al., 1980; Martindale, 1982). MAO inhibition after furazolidone 
administration has been observed in man (Pettinger et al., 1968), rats 
18 
(Stern et al., 1966; Palm et al., 1967), chicken (All and Bartlet, 
1980, 1982), ducklings (Ali and Bartlet, 1982) and turkeys (Powers et 
al., 1983). As MAO was not inhibited in an in vitro model using rat 
liver mitochondria (Stern et al., 1966; Pettinger et al., 1968) it has 
been suggested that furazolidone required metabolic activation before 
it may exert this toxic action. According to Stern et al. (1966) acti-
vation may take place by degradation of the oxazolidone-moiety to 
2-hydroxyethyl hydrazine. Metabolic degradation may occur in the gut 
because intramuscularly injected furazolidone in the chicken did not 
affect MAO-activity in contrast to oral administration (Ali and 
Bartlet, 1980). Additional evidence came from the observation that 
pretreatment of chicken with neomycin reduced the effects of MAO-
inhibition by furazolidone (Ali and Bartlet, 1980). However, no dif-
ference in MAO activity in brain and liver could be observed between 
conventional and germfree rats and therefore it has been proposed that 
the intestine of rats can be excluded as the site for the formation of 
a furazolidone metabolite which is inhibitory for MAO (Yeung and 
Goldman, 1981). Thus, the mechanism of MAO-inhibition by furazolidone 
is not fully understood till now and may also be species specific. 
2.2.2 Toxicity in animals 
When animals are exposed to relatively large amounts of furazolidone 
(100-4000 mg/kg body weight), some acute adverse reactions could be 
observed: anorexia, diarrhea, ataxia, depression and dyspnea (St. 
Omer, 1978). There are large species differences in LDsQ-value after 
oral administration: mouse: 2086-3550 mg/kgbw (Dodd and Stillman, 
1944; St. Omer, 1978), dove: 2375 mg/kgbw (St. Omer, 1978), rabbit: 
2125 mg/kgbw (St. Omer, 1978), guinea pig: 1130 mg/kgbw and 1550 
mg/kgbw for female and male animals respectively (Loeda et al., 1977), 
19 
chicken and turkey: 400-500 mg/kgbw (Cooper and Skulski, 1956). 
Differences in LD5Q-values might be explained by species differences 
MAO inhibition. 
Many adverse effects have been described in the literature caused by 
furazolidone upon exposure during several days or weeks. In Table 4 a 
short review is given of some adverse effects after administration of 
furazolidone to animals. 
2.2.3 Toxicity in man 
As already mentioned, furazolidone is a monoamine oxidase inhibitor in 
humans (Pettinger et al., 1968). 
The most common effect of the drug in man appears to be gastro-
intestinal distress, characterized by nausea and/or vomiting. 
Dizziness, drowsiness, ness, headaches and general malaise have also 
been reported (Phillips and Hailey, 1986). Incidentally, allergic 
contact eczema has been reported (Scharfenberg, 1967) as well as an 
increased activity of alkaline phosphatase in faeces (Frolkis et al., 
1975), disulfiram (Antabuse)-like reactions when treatment with 
furazolidone is combined with consumption of beer, characterized by 
flushing, a slight elevation of temperature and occasionally a 
sensation of tightness in the chest (Phillips and Hailey, 1986; 
Paul and Paul, 1964) or liver damage (Van Esch et al., 1983; IARC, 
1983). 
2.2.4 Mutagenicity 
Many members of the class of the 5-nitrofurans exhibit mutagenic acti-
vity (Tazima et al., 1975; Klemencic and Wang, 1978; McCalla, 1983). 
Using bacterial strains which were deficient in nitro-reductase acti-
vity, no mutagenic activity could be observed, indicating that reduc-
tion of the nitro-group is an essential step for mutagenicity 
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(Rosenkranz and Speck, 1976). Once reduced to stable endproducts, 
mutagenic activity is not likely (McCalla, 1983; Skeggs et al., 1984). 
The mutagenic potency of nitrofurans is greatly influenced by the 
nature of the substituent at the 2-position of the furan ring 
(Ichikawa et al., 1986). 
Furazolidone showed mutagenic activity in many prokaryotic and 
eukaryotic testsystems: single base substitutions in Salmonella 
typhimurium TA 98, TA 100 (Ames-test) or Escherichia coli WP 2 
without the addition of a liver homogenate (Sg-mix) (Lu et al., 1979; 
Ebringer and Bencova, 1980; Ohta et al., 1980; Probst et al., 1981), 
rec-assay (repair-test) in Bacillus subtilis H17 (Ohta et al., 1980), 
the sex-linked recessive lethal test in Drosophila melanogaster 
(Blijleven et al., 1977; Kramers, 1982), the gen-conversion test in 
Saccharomyces cerevisiae D4 (Voogd et al., 1982), the fluctuation test 
in Klebsiella pneumoniae (Voogd et al., 1982), Unscheduled DNA synthesis 
test in primary rat hepatocyte cultures (Probst et al., 1981), 
chromosome breakage and sister-chromatid exchanges (SCE) in human 
peripheral lymphocytes (Cohen and Sagi, 1979), chromosomal anomalies 
in swine lymphocytes (Queinnec et al., 1975; Babile et al., 1978) and 
the hypoxanthine-guanine-phosphoribosyltransferase (HGPRT) test in 
mice L 5178 Y lymphoma cells (Voogd et al., 1982). 
Furazolidone stimulates E.coli to synthesize the rec A + gene product 
(protein X ) , an enzyme which is characteristic of error-prone repair 
functions of damaged DNA (Bryant and McCalla, 1980). Pal and Chatterjee 
(1985) reported the induction of X prophage in E.coli by furazolidone, 
which is regulated upon induction and activation of rec A + protein 
(Klemencic and Wang, 1978). Ames-test results revealed genotoxic 
activity in urine and faeces of furazolidone treated rats (Crebelli 
24 
et al., 1982; Willems and De Raat, 1985). Methanol extracts of rat 
urine and faeces induced an increase in the number of SCE in Chinese 
hamster ovary cells. In the case of methanol extracts of the faeces 
a positive effect could only be observed in the presence of a metabolic 
activation system (Willems and De Raat, 1985). Furazolidone was 
negative in the Unscheduled DNA synthesis test in human fibroblasts 
under aerobic conditions (Tonomura and Sasaki, 1973). 
2.2.5 Carcinogenicity 
Several 5-nitrofurans have been tested in long-term carcinogenicity 
studies and proved to be positive (Morris et al., 1969; Cohen et al., 
1973, 1977; Cohen, 1978; Wang et al., 1984). 
Furazolidone has been evaluated extensively by the Food and Drug 
Administration of the U.S. Department of Health, Education and Welfare 
for carcinogenic activity because of its widespread use in veterinary 
medicine (Anonymous, 1976). In Table 5 the main results are summarized. 
It was concluded that furazolidone induces cancer in rats and mice and 
that "furazolidone must be assumed as a potential human carcinogen and 
safeguards taken to assure no human exposure". To assure this no resi-
dues which may pose a risk of cancer may remain in edible animal 
tissue at the time of slaughter. Since it is not known whether the 
parent drug is carcinogenic and/or one or more metabolites, it was 
stated that "all drug-related residues to which humans may be exposed 
must be assumed to be potential carcinogens unless convincing evidence 
is presented to the contrary". From the Mantel-Bryan extrapolation 
model the upper bound on the total residue concentration in meat of no 
carcinogenic concern was calculated based on a probability of the 
occurrence of cancer of 1 in 1 million with a slope of 1 probit unit 
per log increase In dose at the 99% confidence level: approximately 
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0.9 ng/g (Anonymous, 1984). Because of mutagenic and carcinogenic pro-
perties furazolidone is considered as a "category 1" carcinogen in the 
Netherlands, i.e. in principle a non-carcinogenic dose cannot be 
established and the compound should be absent in human food 
(Anonymous, 1979). 
The International Agency for Research on Cancer (IARC) could not eva-
luate the carcinogenic potential of furazolidone since this agency 
does not consider classified data (Anonymous, 1983). 
2.3 Residues and elimination kinetics of furazolidone 
In general it can be concluded that upon administration of furazoli-
done to swine, chicken, turkey, rat, calve and trout the elimination 
of the parent compound from plasma, muscle, kidney and liver is relati-
vely fast. 
2.3.1 Swine 
Orally administered furazolidone is absorbed from the digestive tract 
by swine to a large extent and excreted in the form of a great number 
of metabolic endproducts. Fourty-eight hours after a single oral dose 
of 39 uCi [14C]-furazolidone 70.5%, 3.2% and 19.1% of total dosed 
radioactivity has be demonstrated in urine, expired air and faeces 
respectively. In a similar study in rats these amounts were 81.5%, 3% 
and 11% respectively of the total radioactive dose administered. 
Radioactivity has been demonstrated in swine kidney, liver, thyroid, 
bile, blood, muscle and fat (Tennent and Ray, 1971). No furazolidone 
(< 0.2 mg/kg) has been detected in liver, kidney, muscle, lung and 
heart 0.5-2 hours after dosing piglets (30-40 kg bw) or pigs (60-70 
kg bw) with a high concentration of furazolidone in the feed (1000 
mg/kg). In the piglets a plasma half-life of 0.45 hours was calculated 
(Yamamoto et al., 1978). 
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Tissue samples taken from swine fed 300 mg furazolidone per kg feed 
for 2 weeks or 150 mg per kg feed for 5 weeks did not contain detec-
table furazolidone residues (< 0.5 yg/kg) 4 hours after feed withdrawal 
(Winterlin et al., 1984). 
Addition of 0.02% Bifuran (a mixture of equal quantities of nitro-
furazone and furazolidone) to the feed of swine for several weeks did 
not result in residues in tissues and blood (< 0.25 mg/kg) (Tapernoux 
et al., 1964). 
Low levels of furazolidone (2-5 ng/g of tissue) have been detected in 
tissues of swine fed 150 mg and 300 mg per kg feed for 35 and 21 days 
respectively, 0 day withdrawal. In tissues taken after a 4 days 
withdrawal period, no residues have been detected (Heotis, 1974). 
2.3.2 Other animals 
Tissues of chickens and turkeys fed 200 mg per kg feed for approxi-
mately 7 weeks and 400 mg per kg feed for 14 days, respectively, 
contained no detectable residues of furazolidone (< 0.5 ug/kg) in any 
of the tissues except the skin (Winterlin et al., 1982, 1984). One 
day after starting treatment of laying hens with 400 mg furazolidone 
per kg feed for 14 days, residues have been detected in eggs. Maximum 
average values reached 0.7 mg/kg. Residues have been detected until 
five days after withdrawal of the drug (> 0.01 mg/kg) (Petz, 1984). 
In White Leghorn birds furazolidone residues have been measured in 
tissues in the order of 3-13 mg/kg of tissue following oral doses of 
10 mg/kgbw/day for 1-10 days. The reported plasma half-life was 42 
hours (Yadava et al., 1986). 
Only traces of furazolidone have been detected in the urine of chickens 
medicated with a single oral dose of 30 mg/kgbw (Craine and Ray, 1972). 
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Relatively low urinary levels of furazolidone have also been reported 
for goats (Pandey et al., 1978) and rats (Crebelli et al., 1982). 
Twenty-four hours after dosing calves with 10 mg furazolidone/kgbw 
for 3 days, no residues have been detected in plasma (< 1 mg/kg) 
(Pietsch et al., 1978). 
Furazolidone has been detected in plasma and milk up to 24 hours and 
12 hours respectively, after a single oral dose of 10 g/kgbw to goats 
(Pandey et al., 1980; Mustafa et al., 1985). Prolongation of the medi-
cation for 5 days, resulted in detectable residues in muscle and liver 
up to 7 days withdrawal (Mustafa et al., 1985). In buffalo, a plasma 
half-life of 2.52 hours has been reported after a single oral dose of 
30 mg/kgbw (Mir and Uppal, 1984). During a 6-days treatment of trouts 
with medicated feed (3% furazolidone in the feed; amount of feed: 1% 
of bodyweight/day), 50 ng furazolidone could be measured per g of 
muscle. After 2.5 day withdrawal, no residues were detected (< 0.5 
Ug/kg) (Schmidt and B'uning-Pf aue, 1985). 
2.4 Biotransformation 
2.4.1 Nltrofurans in general 
In general, it is believed that reduction of the nitro-group is the 
most important metabolic pathway of nitrofurans (Swaminathan and 
Lower, 1978). The initial step involves the transfer of a single 
electron to the nitro-group, resulting in a nitro radical anion. 
Further reaction may lead to the nitroso-derivative and, under 
aerobic conditions, to the formation of the superoxide radical anion 
O2 - which in the presence of superoxide dismutase may form hydrogen 
peroxide. In E. coli the presence of two different types of reductase 
have been postulated: an oxygen sensitive nitroreductase, which 
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transfers 1 electron to the nitro-group, and an oxygen-insensitive 
nitroreductase which does not appear to transfer 1 electron to nitro-
furans, but which may catalyse a 2-electron transfer to nitrofurans, 
resulting in the nitroso-derivative (Peterson et al., 1979). 
This derivative is believed to be further reduced via the hydroxyl-
amino-derivative to the open-chain cyano-derivative (Fig. 2). The 
highly reactive intermediate nitroso- and hydroxylamino-derivatives 
are believed to be responsible for interaction with biological macro-
mulecules as DNA and protein (Swaminathan and Lower, 1978). For 
several nitrofurans the open-chain cyano-derivative has been iden-
tified (Swaminathan and Lower, 1978). 
B 
2e" 
CU^oA* 0=N AoA 
V. 
H 
" 0 9 N / ^ 0 - / \ 0=N^X0'/XR 
Figure 2: Proposed mechanisms of 5-nitrofuran reduction 
(Peterson et al., 1979) 
A: oxygen-sensitive 
B: oxygen-insensitive 
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Several enzymes can transfer electrons to the nltro-group: microsomal 
NADPH cytochrome P-450-reductase, mitochondrial and microsomal 
NADH-cytochrome-b5-reductase, cytosolic xanthine oxidase, aldehyde 
oxidase, DT-Diaphorase (NADPH-dehydrogenase) and Lipoyldehydrogenase 
(Diaphorase II) (Swaminathan and Lower, 1978; Abraham, 1981; Hunder, 
1985). 
Although nitro-reduction is believed to be the main biotransformation 
route, other routes cannot be excluded such as hydroxylation of the 
furan ring as is shown in the case of nitrofurantoin (Jonen, 1980; 
Jonen et al., 1980) and epoxidation of the furan ring, as is postulated 
for methylfurans (Ravindranath et al., 1984). Biotransformation of the 
side-chains of the 5-nitrofurans may also be possible (Swaminathan and 
Lower, 1978). 
2.4.2 Furazolidone 
In the case of furazolidone, several metabolites have been reported to 
be formed as a result of reductive metabolism in vitro and in vivo. 
The identification of the cyano-derivative has been reported in urine 
of rats (Tatsumi and Takahashi, 1982; Tatsumi et al., 1984) and rabbits 
(Tatsumi et al., 1978), as an excretion product in eels (Nakabeppu 
and Tatsumi, 1984), in Escherichia coli (Abraham et al., 1984) and rat 
liver fractions (Tatsumi et al., 1981, Abraham et al., 1984) and after 
investigations using milk xanthine oxidase (Tatsumi et al., 1978, 1981). 
Other identified metabolites from reductive metabolism are the 
5-amino-derivative in a milk xanthine oxidase system (Tatsumi et al., 
1981), the monoacetyl derivative of the aminofuran, the open-chain 
carboxylic acid derivative and a-ketoglutaric acid in the urine of 
rats (Tatsumi et al., 1984) and 2,3-dihydro-3-cyanomethyl-2-hydroxyl-
5-nitro-la,2-di (2-oxo-oxazolidin-3-yl)iminomethylfuro[2,3-b]furan 
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after In vitro metabolism (Tatsumi et al. , 1981). 
Although several metabolites have been identified, approximately 75% of 
urinary metabolites are not identified yet (Tatsumi et al., 1984). 
In urine of swine 2 peaks could be observed after ion exchange frac-
tionation with absorption maxima at 415 nm (Tennent and Ray, 1971). 
This may be the result of 4-hydroxylation of the 5-nitrofuran ring, 
as the corresponding derivative of nitrofurantoin gave an absorption 
maximum at the same wavelength (Jonen et al., 1980). However, its 
structure has not yet been elucidated. 
Under acid conditions hydrolysis of the azomethine linkage may occur, 
resulting in the formation of 3-amino-2-oxazolidone (Paul et al., 1960). 
Schmid (1985) suggested that this hydrolysis product is further meta-
bolised into carbondioxide, ethene and hydroxyhydrazin. 
3. Objective of the investigation 
Considering the data available on furazolidone it can be concluded 
that essential information on its kinetics and biotransformation in 
swine is lacking. For instance the results of the studies made by 
Tennent and Ray (1971) suggest that residues may remain present in 
edible tissues, which could be attributed to possible metabolite(s). 
However, the identity of the metabolite(s) is yet unknown. Reduction 
of the nitro-group of furazolidone, which seems to be an important 
biotransformation route, may lead to the formation of unstable 
intermediate metabolites which subsequently may react with proteins 
or DNA. Covalent binding of drugs to tissue macromolecules may result 
in residues which are persistently present in edible tissues. Con-
sidering the carcinogenic properties of furazolidone and its wide-
spread use in mass-medication of food producing animals, it is of 
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the importance from the food consumer point to identify the reactive 
properties of possible metabolites present in the edible parts of ani-
mals treated with this drug. 
The studies presented in this thesis were undertaken to obtain a better 
understanding of the biotransformation and kinetic behaviour of 
furazolidone in swine. For this purpose an analytical method has been 
developed for the determination of furazolidone in swine plasma, fat, 
muscle, kidney, liver and urine. 
Subsequently, experiments were conducted using two different 
approaches: 
- kinetic studies in the target animal to determine the elimination 
kinetics of furazolidone and its metabolites from plasma and tissues 
upon oral administration of furazolidone 
- model systems using rat and swine liver microsomes to elucidate bio-
transformation routes and reactive intermediates responsible for the 
interaction with biological macromolecules. 
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Determination of furazolidone in swine plasma, muscle, liver, kidney, 
fat and urine based on high-performance liquid chromatographic sep-
aration after solid-phase extraction on Extrelut® 1 
LOUIS H. M. VROOMEN*, MARCEL C. J. BERGHMANS and TEUNIS D. B. VAN DER STRUIJS 
State Institute for Quality Control of Agricultural Products (RIKILT), Bornsesteeg 45, 6708 PD Wage-
ningen (The Netherlands) 
(Received March 14th, 1986) 
Furazolidone [N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone], which is a 
nitrofuran, has been described as a potent antimicrobial agent for therapeutic and 
prophylactic purposes in pig, poultry and cattle1. Since furazolidone exhibits muta-
genic and carcinogenic properties2-4, the amount of furazolidone residue in edible 
products of food-producing animals treated with furazolidone should be minimal. 
This requires sensitive analytical methods for the detection of furazolidone in liver, 
muscle, fat and kidney. In addition, methods for the detection of furazolidone in 
plasma or urine may be needed for screening purposes and pharmacokinetic studies. 
Many different methods have been described for the detection of furazolidone in 
tissues, milk, eggs, plasma and urine5-16. 
Up till now, no suitable sensitive method has been described for the detection 
of furazolidone in plasma, muscle, liver, kidney, fat and urine. In this study, a rela-
tively fast and sensitive high-performance liquid chromatographic (HPLC) method 
is described for the determination of furazolidone in plasma, muscle, liver, kidney, 
fat and urine of swine using a simple clean-up procedure based on solid-phase ex-
traction on a commercially available disposable column. Only 1 g of sample is re-
quired. 
EXPERIMENTAL 
Chemicals and solvents 
Water was purified over a Millipore Milli-Q water purification system. Ethyl 
acetate (LiChrosolv 868), acetonitrile (LiChrosolv 30), «-hexane (4391), acetic acid 
(62) and sodium acetate (6268) were purchased from Merck (Darmstadt, F.R.G.). 
Furazolidone was a gift from Orphahell (Mijdrecht, The Netherlands). 
Acetate buffer solution (1.0 M). The solution contained 41 g of sodium acetate 
and 30 g of acetic acid in 1 1 of water. 
Stock solutions. Stock solutions of furazolidone in acetonitrile were prepared. 
The final concentration range was 1-1000 ng/ml eluent. 
0021-9673/86/S03.50 © 1986 Elsevier Science Publishers B.V. 
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Sample preparation 
Plasma, urine. A 1-ml aliquot of plasma or urine was applied directly to a 
Merck Extrelut® 1 column (Merck 15371). After an equilibration period of 10 min, 
the drug was eluted with 6 ml of ethyl acetate. The eluate was collected in tubes and 
evaporated to dryness under nitrogen. The residue was dissolved in 300 pi of eluent. 
Muscle, liver, kidney, fat. A 1-g quantity of frozen sample (liquid nitrogen) was 
pulverized and 2 x 6 ml of ethyl acetate were added and mixed for 1 min. After 
centrifugation for 5 min at 3000 g, the water phase was frozen (alcohol-dry ice). The 
ethyl acetate was collected in tubes and evaporated to dryness under nitrogen at 
room temperature. To remove fat from samples of liver, kidney and fat, the residue 
was dissolved in 5 ml of acetonitrile and 2 x 2 ml of hexane were added and mixed 
for 1 min. After centrifugation for 5 min at 3000 g, the hexane was removed and the 
acetonitrile was evaporated to dryness under nitrogen. The residues of samples of 
muscle, liver, kidney and fat were dissolved in 1 ml of a methanol-water mixture 
(25:75) and these solutions were applied to a Merck Extrelut 1 column. After an 
equilibration period of 10 min, the drug was eluted and prepared for HPLC as de-
scribed for plasma and urine. Since furazolidone decomposes under the influence of 
daylight17, brown glassware has been used and the experiments were performed 
under artificial yellow light (Pope FT 40W/16). 
High-performance liquid chromatography 
Liquid delivery system: Waters 6000A; automatic injection system: Waters 
710B; detector: Kratos Spectroflow 773; absorbance recorded at 362 nm; recorder: 
Kipp BD41. 
Analytical column: Shandon Hypersil ODS 5 (250 x 4.6 mm I.D.) (Chrom-
pack); precolumn: Brownlee Labs. OD-GU RP-18 (30 x 4.6 mm I.D.). 
Eluent: water-acetate buffer-acetonitrile (675:75:250); flow-rate: 1 ml/min; run 
time: 15 min (urine: 20 min); injection volume: 50-100 pi. 
RESULTS AND DISCUSSION 
Because of the effective clean-up procedure, isocratic HPLC could be used. In 
blank samples of swine, no interfering peaks could be detected at 362 nm. Concen-
trations of furazolidone were calculated by comparing the peak heights from spiked 
samples with the peak heights from corresponding standard solutions, containing the 
same amounts of furazolidone. As shown in Fig. 1, linearity exists between the con-
centration of furazolidone and peak height in the range of 1-1000 ng/ml standard 
solution. Such a linearity was also found for spiked samples. 
Recovery data for swine samples spiked with furazolidone in a concentration 
range of 1-1000 ng/ml (or ng/g) of sample are shown in Table I. Each result rep-
resents the average of six determinations. The mean overall recovery for plasma 
(«= 30) is 96.4 ± 3.3, muscle (« = 30): 98.8 ± 4.4, liver (« = 30): 86.7 ± 6.4, kidney 
(«=30): 89.8 ± 4.9, fat (« = 30): 81.8 ± 5.1 and urine (« = 24): 91.2 ± 2.3. 
The sensitivity of the method, expressed as three times the background of a 
blank sample, was 1 ng/ml for plasma, 2 ng/g for muscle, liver, kidney, fat and 25 
ng/ml for urine. 
In Fig. 2, the chromatograms of a blank and a spiked liver sample (5 ng/g) 
and a blank and spiked urine sample (25 ng/ml) are shown. 
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1. Concentration of furazolidone in standard solution (ng/ml) as a function of peak height (mm) 
measured in the chromatogram. 
The method proved its usefulness in a study in which a pig of approximately 
90 kg body weight was treated with furazolidone by feed medication at a concentra-
tion of 300 mg/kg. Total daily feed intake was calculated on the basis of 4% of total 
body weight, dosing twice daily at 9.00 h and 16.00 h. Blood samples were collected 
via a syringe in the vena jugularis into heparinized tubes (Sarstedt 02.1065). Plasma 
was separated by centrifugation and immediately analysed, since a time-dependent 
decrease of furazolidone has been reported16. As an example, the chromatograms of 
furazolidone in plasma, 1 and 7 h after the last dosage at 9.00 h on day 10 of treat-
ment, are shown in Fig. 3. Furazolidone concentrations were 104 and 6 ng/ml, re-
spectively. 
It can be concluded that the method described is suitable for the detection of 
furazolidone at the ng/ml or ng/g level in plasma, muscle, liver, kidney, fat and urine. 
The method is simple and requires only small amounts of sample and reagents. The 
TABLE I 
PERCENTAGE FURAZOLIDONE RECOVERED FROM SPIKED SAMPLES OF SWINE IN A 
FINAL RANGE OF 0-1000 ng/ml OR ng/g OF SAMPLE (n = 6; MEAN ± S.D.) 
Sample 
Plasma 
Muscle 
Liver 
Kidney 
Fat 
Urine 
Concentration 
1 ppm 
92.3 ± 2.3 
101.6 ± 5.3 
91.2 ± 2.5 
83.5 ± 3.0 
84.2 ± 4.4 
8S.8 ± 2.1 
range ofsam 
100 ppb 
95.3 ± 0.6 
98.9 ± 4.0 
82.7 ± 2.7 
86.5 ± 1.2 
84.0 ± 3.5 
93.4 ± 0.6 
pies spiked with 
50 ppb 
101.0 ± 2.4 
95.4 ± 3.6 
88.4 ± 4.7 
91.8 ± 2.3 
76.1 ± 2.7 
90.8 ± 2.3 
furazolidone 
25 ppb 
— 
-
-
-
— 
91.8 ± 0.9 
10 ppb 
96.2 ± 1.5 
99.4 ± 3.3 
82.2 ± 5.1 
95.1 ± 1.8 
78.6 ± 4.7 
-
5 ppb 
97.4 ± 1.2 
99.2 ± 4.4 
89.2 ± 9.8 
91.9 ± 4.0 
86.3 ± 1.2 
-
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Fig. 2. High-performance liquid chromatograms of blank and spiked samples of swine liver (A: blank, B: 
5 ng/g furazolidone) and swine urine (C: blank, D: 25 ng/ml furazolidone) (F = furazolidone). (A, B) 
X = 362 nm; speed: 0.5 cm/min; sensitivity of detector: 0.002 a.u.f.s.; sensitivity of recorder: 10 mV; 
injection volume: 50 p\. (C, D) X = 362 nm, speed: 0.5 cm/min; sensitivity of detector: 0.005 a.u.f.s.; 
sensitivity of recorder: IOJTIV; injection volume: 50 |xl. 
Fig. 3. High-performance liquid chromatograms of furazolidone in plasma of a pig, 1 h (A) and 7 h (B) 
after the last administration of furazolidone on day 10 of treatment (F = furazolidone). (A) X = 362 nm; 
speed: 1 cm/min; sensitivity of detector, underline: 0.1 a.u.f.s., upperline: 0.01 a.u.f.s.; sensitivity of re-
corder: 10 mV; injection volume: 50 /jl. (B) X = 362 nm, speed: 1 cm/min; sensitivity of detector, underline: 
0.1 a.u.f.s., upperline: 0.005 a.u.f.s.; sensitivity of recorder: 10 mV; injection volume: 50 /A. 
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NOTES 
total time that elapsed between sample collection and final determination of the 
amount of furazolidone varied between 30 and 60 min. The method may be used for 
screening purposes in plasma or urine of food-producing animals treated with fur-
azolidone, and in pharmacokinetic studies. 
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After dosing piglets orally with 14C-furazolidone (75 mg/animal/day) for 10 days, no 
accumulation of the drug could be detected in the blood. The half life of furazolidone in blood 
after the last oral administration on day 10 was 60 minutes. In blood, radioactivity reached a 
plateau of approximately 10 ppm equivalents of parent compound at day 6 of the medication. 
After a relatively fast decrease of radioactivity during the first day of the withdrawal period, a 
much slower decrease could be observed in the blood with a half life of approximately 6 days. 
1 day after stopping the medication almost all the radioactivity in plasma appeared to be 
associated with plasma proteins. Furazolidone could not be detected in muscle, fat, kidney 
and liver of piglets two hours after the last administration. However, the level of radioactivity 
was 5 7-7-2,ug equivalents per gram in muscle, 6-0-9-2/ig equivalents per gram in fat, 
30 1 ,ug equivalents per gram in kidney and 32 9//g equivalents per gram in liver. After a 
withdrawal period of 14 days 0-9-4-3n% equivalents per gram could be detected in the 
analysed tissues. It also appeared that respectively 14 0%, 9 3% and 35 0% of the residual 
radioactivity could not be extracted from liver, kidney and muscle of piglets sacrificed 2 
hours after the last administration of "C-furazolidone and 27 0%. 312% and 55 6% of the 
residual radioactivity from liver, kidney and muscle respectively of piglets sacrificed after a 
withdrawal period of 14 days. DNA-binding of HC-furazolidone in tissues of piglets varied 
from 87-382 pmol equivalents of parent compound per mg DNA. 61% of total dosed 
radioactivity had been excreted via the urine and 18 1% via the faeces. No radioactivity 
could be measured in the expired air. 
Introduction 
Furazolidone [N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone] is a veterinary 
drug widely used as an antimicrobial agent for therapeutic and preventive purposes in 
pigs, poultry and cattle (Brander. and Pugh 1971; Rossoff 1974). Because of the 
mutagenic (McCalla 1983) and supposed carcinogenic activities (Food and Drug 
Administration 1976) residues should be avoided in edible tissues of animals treated 
with furazolidone. The depletion of furazolidone from muscle, kidney and liver tissue 
upon oral administration to chickens and pigs is relatively fast: immediately after the 
last administration, residual concentrations of furazolidone are below the limit of 
detection (<0-5ppb) (Winterlin et al. 1984). However, information concerning the 
metabolism of furazolidone in food producing animals is scarcely available. In general, 
it is believed that reduction of the nitro group is the main metabolic pathway of 
nitrofurans (Swaminathan and Lower 1978). Several metabolites of furazolidone upon 
in vitro and in vivo reduction have been identified (Tatsumi et al. 1978, 1981, 1984; 
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Abraham et al. 1984; Nakabeppu and Tatsumi, 1984; Vroomen et al. in press). 
Information concerning the formation and depletion of metabolites of furazolidone and 
the kinetics of these processes upon oral administration of furazolidone to food 
producing animals during several days is lacking. 
The results obtained in this study provide information on the metabolism of 
furazolidone and on the pharmacokinetic behaviour in blood and tissues of piglets upon 
oral administration of 14 C-furazolidone during 10 days at a dose level which is 
commonly used in veterinary practice (300 mg per kg feed). Furthermore the interaction 
of furazolidone with plasma protein and DNA and the amount of non-extractable 
residues of furazolidone or metabolites in edible tissues are reported. 
Materials and methods 
14
 C-furazolidone 
14
 C-furazolidone was labelled in the methylene groups of the oxazolidone moiety 
(figure 1). The specific activity was 202//Ci/mg; the radiochemical purity was > 99% 
by TLC (toluene: acetic acid: acetone: water = 600:240:80:25) and HPLC. 
02l\l / \ 0 / V C = N - N H 
H. 
/ / 
0 
0 
H2 
Figure 1. Chemical structure of furazolidone. l4C-label in the methylene groups (*) of the oxazolidone 
moiety. 
A nimal handling and sample collection 
The experiment was divided into three successive phases: 
(1) an initial period of 2 weeks for acclimatization and surgical purposes; 
(2) a medication period of 10 days followed by 
(3) a withdrawal period of 0 and 14 days. 
At the beginning six three-weeks-old male piglets (Dutch Landrace x Great 
Yorkshire) were placed in the radionuclide unit at IGMB/TNO-ILOB, Wageningen, 
The Netherlands. The animals were individually housed. After an acclimatization period 
of 1 week, catheters were implanted in the left vena jugularis which functioned 
satisfactorily during the whole experiment. After 4-5 days, when the animals were 
recovered, permanent stomach tubes for the administration of furazolidone preparations 
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were installed which were tolerated well by the animals. At the same time plastic bags 
were attached for the separate collection of faeces. 
At the start of the medication period the animals (mean weight ±S.D.: 
5900 ± 472 gram) were divided into 3 groups of 2 animals: 
Group I: control animals 102 and 103. 
Group II: '4 C-furazolidone treated animals 101 and 106. 
Group III: unlabelled furazolidone treated animals 104 and 107. 
A standard piglet diet without antibiotics was provided twice daily at 9- 00 h and 
16 00 h. The daily amount of feed to be administered was calculated as 4% of the body 
weight with a maximum of 250 gram/animal/day during the period of furazolidone 
administration. Feed restriction was applied in order to ensure minimal variations in the 
individual weights at the end of the medication period. 
Furazolidone was dosed twice daily during feeding time via the stomach tube. It 
was given as a 1% suspension in a 5% gelatine gel. The total daily amount was 75 mg 
furazolidone/animal, which corresponded to approximately 12 mg per kg body weight. 
The animals had free access to tap water. The waste water was collected, the amount 
registered and samples of it were taken for radioactivity measurement. 
Faeces and urine were collected separately. Twice daily, just before feeding time, 
total amounts of excreta were registered; immediately after collection, urine and faeces 
were homogenized and samples were taken for radioactivity measurement. 
Each day the cages of the piglets of group II were cleaned by spraying 
water: methanol (50:50 v/v). The wash liquid was collected, the total volume registered 
and samples were taken for radioactivity measurement. In order to prevent 
contamination of the wash liquid of the cages with solid particles (feed, hair, scales of 
the skin, etc.) the wash liquid was filtered through a fibre glass filter during collection. 
This procedure ensured that the wash liquid contained only dried urine residues of the 
cages; at the end of the experiment approximately 5% of the total dose of radioactivity 
was present in this fraction. Two hours after each morning feeding period samples of 
blood were collected via the permanent catheter into heparinized tubes (Sarstedt 
02-1065). Samples were immediately analysed for the concentration of furazolidone in 
blood and plasma since a time dependent decrease of furazolidone in blood has been 
reported (Veale and Harrington 1982). Plasma was separated by centrifugation. The 
protein fraction of the plasma was separated by ultrafiltration (Amicon Centrifree 
Micropartition System). Radioactivity in the protein fraction was calculated from the 
difference in radioactivity of the whole and protein free plasma. 
During the medication period the expired air was qualitatively analysed for 
radioactivity. 
After the last administration of furazolidone on day 10, samples of blood and 
plasma were collected at regular time intervals from the treated animals 107 and 106. 
At day 10 of the medication period, 2 hours after the last administration, one 
animal of each group (numbers 102, 106 and 104) was sacrificed by exsanguination via 
the permanent catheter in the vena jugularis; the other animals (numbers 103, 101 and 
107) were sacrificed after a withdrawal period of 14 days. Samples were taken of the fat 
of the abdominal cavity, subcutaneous fat, liver lobus centralis dexter, liver lobus 
centralis sinister, kidneys, musculi longissimi dorsi, musculi psoas major, musculi 
biceps, musculi triceps and musculi quadriceps for analysis of the concentration of 
furazolidone and the level of radioactivity. 
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Samples were taken of the skin, bladder content, spleen, stomach, stomach 
content, small intestine, small intestine content, large intestine, large intestine content, 
gall bladder, bile, pancreas, lungs, heart, testicles, tongue and brains for radioactivity 
measurements only. All samples for furazolidone analysis were immediately frozen in 
liquid nitrogen and stored at — 40°C. Samples for radioactivity measurements were 
stored at -20°C. 
Analysis of furazolidone 
Analytical procedures were performed under artificial yellow light (Pope FT 40 
W/16), because of the instability of furazolidone in daylight (Kalim 1985). 
Frozen tissue (1 g) was pulverized and extracted with ethyl acetate. After evap 
oration of ethyl acetate the residue was dissolved in water: methanol (75:25v/v) 
and subsequently treated in a clean-up procedure by partitioning on a Merck 
Extrelut-1R column. Blood (1 ml) and plasma (1 ml) were directly processed in this 
clean-up procedure. The concentration of furazolidone in the eluates was analysed by 
HPLC with UV-detection at 362 nm. The limit of detection was 2 ppb in tissue and 
1 ppb in blood and plasma (Vroomen et al. 1986). 
HPLC 
Pump: Waters Associates 6000 A; automatic injection system: Waters 710 B; UV-
detector: Kratos Spectrofiow 773; recorder: Kipp BD41. Column: Chrompack 
Hypersil 5 ODS (250x4-6 mm); precolumn: Brownlee Labs OD-GU RP18 
(30 x 4-6 mm). Eluent: water-0 1 M acetate buffer pH 5 0-acetonitrile (675 :75 :250). 
Flow rate: 1 ml/min. Absorbance was recorded at 362 nm. Run time: 15 min. 
Preparation of samples for radioactivity measurements 
Tissue. Samples of 0-5-1-5 g were solubilized in a mixture of 5 ml Soluene-350R 
(Packard) and 1 ml isopropanol at 60°C for 8-12 hours until a clear solution was 
obtained. After addition of an anti-foam agent, the solution was bleached by adding 
0-5 ml 30% H2O2 and successively incubated for 15 minutes at room temperature and 
45 minutes at 60°C. Then the samples were mixed with 15 ml Dimilume-30R (Packard). 
Blood and Plasma. 0-2 ml blood or 0-5 ml plasma were solubilized in a mixture of 
1 ml Soluene-350R and 1 ml isopropanol at 60°C for 1 hour. Bleaching procedures were 
the same as described for tissue. 
Faeces. Samples of 0-1 g were solubilized in a mixture of 2 ml Soluene-350R and 1 ml 
isopropanol at 60°C for 24 hours. After the standard bleaching procedure an additional 
bleaching with 0-2 ml 30% H2O2 at room temperature was necessary. Subsequently the 
samples were mixed with 19 ml Dimilume-30R. 
Urine, waste water and wash liquid. Samples of 1 ml were mixed with 15 ml 
Dimilume-30R. 
Radioactivity measurements. The radioactivity in all samples was measured in a 
Philips liquid scintillation counter (type PW 4700). Counting efficiency was calculated 
by means of an external standard-counting procedure. The amount of radioactivity is 
expressed as fig, equivalents of parent compound per g of tissue. For all calculations it is 
assumed that no change in specific activity has taken place. 
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Non-extractable radioactivity 
In order to determine the non-extractable radioactivity in liver, kidney and muscle, 
samples of 1 g of frozen material were pulverized and extracted with water (4 times), 
acetonitrile (2 times), ethyl acetate (2 times), 1 M urea (1 times), methanol (3 times), 
ethanol (2 times) and ethanol-chloroform-diethylether (2:2:1). The radioactivity 
measured in the tissue residue after these extraction steps was defined as non-extract-
able. Furthermore the amount of radioactivity was also measured in the ultrafiltrate of 
water extracts of the various tissues. 
Isolation and purification ofDNA 
The DNA was isolated according to Jeffreys and Flavell (1977) with several 
modifications. 
Frozen tissue (1 g) were pulverized and homogenized in 20 ml of ice-cold 
150 mM NaCl, 1 0 0 M EDTA (pH 8 0); sodium dodecylsulphate was added to a final 
concentration of 1% and NaC104 to 1 M. 
The lysate was extracted twice with an equal volume of chloroform isoamyl alcohol 
(24:1) and the DNA was precipitated by adding 2 ml of 2 M Na acetate (pH 5-6) and 
20 ml of isopropanol. 
After washing with ethanol, the DNA was dissolved in 12 ml TNE (TNE = 
50 mM, Tris-HCl, 100 mM NaCl, 5 mM EDTA, pH7-5). After incubation with 
pancreatic ribonuclease and proteinase, the solution was 10 times extracted with equal 
volumes of phenol/m-cresol/8-hydroxyquinoline (100:14:0-1). In order to remove 
residues of phenol, the water phase was subsequently extracted 5 times with 
diethylether. The DNA was precipitated by addition of ethanol. After washing with 
ethanol and drying, DNA was dissolved in 1 ml 10 mM Tris HC1 pH 7-5. The amount 
of DNA was determined by spectrophotometry based on A26o = 20 mg _ 1 . The purity 
was determined by the ratio's A260/A230 and A26o/A28o- Where necessary an additional 
purification was used by cesium chloride gradient centrifugation as described by 
Maniatis etal. (1982). 
Results 
Animal condition and body weight gain 
At the start of the medication period animal 106 showed a decreased appetite 
which may have been caused by an inflammation in the left foreleg. It was treated with 
a single intramuscular injection of Depomycine 15/25R (Gist-Brocades, The 
Netherlands). Within 1 day the piglet recovered its appetite and within 3 days the 
inflammation disappeared. The piglets showed a regular weight gain. During the 
medication period the mean daily body weight gain was 156 ± 18 g (n = 6), and during 
the withdrawal period 239 ± 32 g (n = 3). 
Kinetic studies 
Blood and plasma. Mean levels of furazolidone in blood during medication varied 
between 0-31 and 0-53,ug/ml while in plasma similar values were observed. No 
accumulation of furazolidone during the medication period could be observed in blood 
or plasma. 
Mean blood and plasma levels of furazolidone upon oral administration on day 10 
are shown in figure 2. The concentration of furazolidone reached a maximum value of 
835 and 955ngml~' in blood and plasma respectively within 30 minutes after 
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administration, followed by a decrease which resulted in levels below the limit of 
detection of 1 ng • ml -1 3-4 hours after the last administration. The half life (t1/2) of 
furazolidone in blood and plasma was approximately 60 minutes. 
1000— 
• • - BLOOD 
•* * - PLASMA 
180 240 
time (minutes) 
Figure 2. Blood and plasma levels of furazolidone (ng per ml) after oral administration to piglets at day 10 
(« = 2 except at f=180min.: n=\ because animal 106 was slaughtered 2 hours after the last 
administration). 
In contrast to the parent compound furazolidone, an increasing amount of 
radioactivity had been observed in blood and plasma during the medication period. 
Values of radioactivity as measured in plasma are shown in figure 3. 
5-6 Days after initiation of the medication, maximum levels of approximately 
9—10//g equivalents of parent compound per ml were measured. A relatively fast 
decrease of radioactivity in blood and plasma had been observed during the first day 
after the last administration of l4C-furazolidone, followed by a much slower decrease 
during the next 13 days with a half life of approximately 6 days. During the withdrawal 
period the amount of radioactivity measured in blood was approximately 1 fig 
equivalent of parent compound per ml higher than that in plasma. At the end of 
the withdrawal period, residual values of 2-6 and \-5fig equivalents of parent 
compound per ml were still present in blood respectively plasma. The amount of 
radioactivity associated with the plasma protein fraction is shown in figure 4. One day 
after the start of the medication approximately 40% of total radioactivity in plasma was 
measured in the protein fraction; at the end of the medication period approximately 
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75% and during the withdrawal period nearly all radioactivity was found in the plasma 
protein fraction. No radioactivity could be detected in the ultrafiltrates of the plasma 
protein fraction of samples taken at day 5 of the withdrawal period which repeatedly 
had been washed with water and methanol. Furthermore, no absorption of 
l4C-furazolidone to the membrane could be detected. 
Urine, faeces, expired air. The main excretion pathway of radioactive labelled 
material proved to be the urine. At the end of the medication period 52% of the total 
dose of radioactivity was excreted via the urine while during the withdrawal period an 
additional 4% was collected (figure 5). 
Taking the radioactivity of the wash liquid of the cages into account the total 
excretion of radioactivity via the urine at the end of the experiment was found to be 
61%. 
Negligible amounts of radioactivity were measured in the waste drinking water 
(< 0-5% of total dose). 
At the end of the medication period 15% (animal 106) and 18% (animal 101) of 
the total dosed radioactivity was excreted via the faeces and during the withdrawal 
period an additional 3% (figure 5). No radioactivity associated with volatile metabolites 
or endogeneously formed 14C02 was found in expired air. 
Tissues. None of the animals showed abnormalities at autopsy. The parent com-
pound furazolidone could not be detected in muscle, fat, kidney and liver (<2 ng per g) 
immediately after the medication period of 10 days even if 5 g of tissue instead of 1 g 
were taken for analysis. 
Mean levels of radioactive residues in various tissues, calculated as fig equivalents 
of the parent compound per g immediately after the medication period and after the 
withdrawal period of 14 days are shown in table 1. 
Immediately upon cessation of the medication highest levels of radioactivity were 
found in bile, liver and kidney (811 , 32-9 and 30-1 //g equivalents per g respectively). 
In muscle 5 1-1-2 fig equivalents per g were measured. After the withdrawal period of 
14 days, radioactivity levels detected in the tissues had decreased substantially and 
varied between 0-9-3 1 fig equivalents'per g. Recovery of total dosed radioactivity in 
this experiment was 80%. 
Non-extractable radioactivity. Table 2 shows that 14% of the radioactivity (cor-
responding to 4-8 fig equivalents of parent compound per g) is non-extractable from 
liver tissue immediately after the medication period of 10 days. 
37-8% of total residual radioactivity in liver tissue was found in the ultrafiltrate of 
water extractable material, indicating that the remaining 44-1% of total residual radio-
activity (corresponding to 53-8% of radioactivity in water extract) was associated with 
water soluble material which did not pass through the membrane. After the withdrawal 
period of 14 days 0-8 fig equivalents of parent compound per g were present as non-
extractable material representing 270% of total residual radioactivity. In kidney 2-9 
and 0-9fig equivalents per g (9-3% and 31-2% of total residual radioactivity 
respectively) and in the musculus biceps 2-3 and 1-2 fig equivalents per g (35 0% and 
55-6% respectively of total residual radioactivity) were non-extractable after 0 and 14 
days respectively withdrawal time. 
Recoveries (mean±S.D.; n = 6) of radioactivity after the extraction steps were 
100% ± 4%. 
61 
L.H.M. Vroomen et al. 
68 
Kinetics of l4C-furazolidone 
Table 1. Mean level of radioactivity (ppm-equivalents of parent compound) in tissue 0 and 
14 days after oral administration to piglets of 14C-labelled furazolidone during 10 
days. 
Tissue 
Skin, back 
Skin, abdomen 
Subcutaneous fat 
Fat of the abdominal cavity 
Liver 
Kidney 
Musculus longissimus dorsi 
Musculus psoas major 
Musculus biceps 
Musculus triceps 
Musculus quadriceps 
Tongue 
Brains 
Bladder 
Spleen 
Stomach 
Small intestine 
Large intestine 
Gall bladder 
Bile 
Pancreas 
Lung 
Heart 
Testicle 
n 
2 
2 
2 
2 
4 
4 
6 
6 
6 
6 
6 
2 
2 
2 
2 
2 
2 
2 
1 
2 
2 
4 
2 
4 
0 Days after the 
medication period 
(animal 106) 
7-3 
9 
6 
9 
32 
30 
6 
7 
6 
6 
5 
8 
7 
9 
11 
20 
12 
11 
50 
81 
10 
10 
8 
1 
0 
2 
9 
1 
4 
2 
5 
4 
7 
1 
6 
7 
4 
6 
6 
0 
3 
1 
4 
9 
3 
115 
n 
2 
2 
2 
2 
4 
4 
6 
6 
6 
6 
6 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
4 
2 
4 
14 Days after the 
medication period 
(animal 101) 
3-5 
2 
4 
2 
3 
3 
2 
2 
2 
2 
2 
1 
1 
1 
2 
1 
0 
1 
2 
1 
1 
2 
1 
9 
3 
9 
1 
0 
0 
1 
1 
1 
0 
9 
6 
9 
1 
9 
9 
3 
0 
1 
9 
3 
9 
2 3 
Table 2. Radioactivity in several extraction fractions of tissues of piglets as percentage of the total residual 
radioactivity after a withdrawal period of 0 and 14 days. 
Tissue 
Days of withdrawal 
Liver 
0 14 
Kidney 
0 14 
Muscle 
0 14 
Water (4 x ) 
in ultraflltrate 
Acetonitrile (2 x ) 
Ethyl acetate (2 x ) 
lMUrea ( l x ) 
Methanol (3 x ) 
Ethanol (2 x ) 
Ethanol/chloroform/ether 
2/2/1 ( 2 x ) 
Non-extractable 
Recovery 
81 9 
37-8 
0 7 
0 7 
0 5 
1 4 
< 0 1 
0 1 
14 0 
4 8 f 
6 6 0 
19 4 
0-7 
1 1 
2-8 
0-9 
< 0 1 
< 0 1 
2 7 0 
0 8 | 
8 8 1 
53 9 
0 5 
0 6 
0-5 
0-8 
< 0 1 
0 1 
9 3 
2-9f 
59-5 
15 2 
2-8 
2 0 
0 9 
3-3 
0.1 
0 2 
3 1 2 
0 9 f 
59 9 
36 5 
1 4 
1 4 
0 9 
1 1 
< 0 1 
0-2 
3 5 0 
2-3f 
39-
15 
0 
0 
0 
1 
0-
0 
55-
1-
0 
6 
9 
8 
7 
2 
3 
6 
2t 
104-3% 96-2% 1050% 99 3% 96 3% 99-4% 
t ppm-equivalents of parent compound 
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Interaction of furazolidone with DNA. The purity of the isolated DNA was 
determined by the A260/A23o and A260/A280 ratio's. These were 2-41 ± 0 0 9 and 
1 -86±0 05 respectively (n=18) indicating that total protein amount was < 0 0 1 % 
(Markov and Ivanov, 1974). Table 3 shows interaction of furazolidone with DNA 
expressed as pmol equivalents of parent compound per mg DNA. 
Table 3. DNA binding (pmol equivalents of parent compound/mg DNA) in 
tissue of piglets 0 and 14 days after oral administration to piglets of 
l4C-labelled furazolidone during 10 days. 
Tissue 
Spleen 
Pancreas 
Liver 
Kidney 
Lung 
Heart 
Muscle 
Brains 
Tongue 
0 Day after the 
medication period 
240 
382 
186 
372 
279 
130 
139 
57 
165 
14 Days after the 
medication period 
102 
119 
106 
114 
87 
106 
118 
89 
82 
Discussion 
The main excretion pathway of 14C-material proved to be the urine. At the end of 
the experiment 61% of total dosed radioactivity had been detected in the urine of which 
approximately 90% already had been excreted at the end of the medication period of 10 
days. 15-18% of total dosed radioactivity had been excreted via the faeces by piglets at 
the end of the medication period, with an additional 3% during the withdrawal period. 
Similar results have been reported in a study with a Yorkshire barrow after oral 
treatment with 14C-furazolidone, in which 70-5% had been excreted via the urine and 
19-1% via the faeces and in a similar test with rats: 81-5% in urine and 11 0% in faeces 
(Tennent and Ray 1971). 
Maximum levels of furazolidone in plasma of piglets were achieved within 30 
minutes after oral administration, reached approximately 1 fig per ml and disappeared 
very fast (calculated half life: 60 minutes). Furazolidone inhibits the growth of micro-
organisms in a minimal concentration range of 1-10 fig per ml; for Proteus species and 
Pseudomonas aeruginosa minimal concentrations up to 300 fig per ml are necessary 
(Van Esch et al. 1983). So after oral administration to piglets furazolidone seems not to 
be effective against other than gastrointestinal infections. In older piglets, weighing 
30-40 kg, maximum levels in the serum after oral treatment with furazolidone in the 
feed (1000 mg per kg feed) were achieved within 30-60 minutes and reached 3-8 fig per 
ml. The half life was 27 minutes (Yamamoto et al. 1978). This difference in half life may 
be due to changes with age in both pathways contributing to excretion and metabolism. 
Nitroreduction is believed to be the major metabolic pathway of nitrofurans 
(Swaminathan and Lower 1978). Short et al. (1972) reported that the rate of 
nitroreduction of p-nitrobenzoic acid in liver of swine increased from 655 nmol per g of 
tissue for a 6 weeks old piglet to 905 nmol per g of tissue for an adult swine. 
In buffalo the half life of furazolidone in plasma after a single oral dose of 30 mg/kg 
body weight was 2-52 hours (Mir and Uppal 1984). 
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Compared with furazolidone itself, the half life of radioactivity in plasma upon oral 
administration of 14C-furazolidone to piglets during 10 days was much higher indicating 
that the depletion of metabolites of furazolidone from plasma was much slower than 
that of furazolidone itself. It appeared that one day after stopping the medication almost 
all the radioactivity was associated with the plasma proteins. 
No furazolidone could be detected in liver, kidney, fat and muscle 2 hours after 
stopping the medication. Comparable results have also been reported by Winterlin et al. 
(1984). However, radioactivity could be detected in all tissues examined at the //g/g level 
(radioactivity expressed as equivalents of parent compound), even 14 days after 
stopping the medication. The major part of extractable radioactivity could be extracted 
by water. Previous studies have identified several metabolites of furazolidone. The open 
chain cyano-derivative 3-(4-cyano-2-oxobutylideneamino)-2- oxazolidone appeared to 
be an important end product of reductive metabolism in rabbits (Tatsumi et al. 1984), 
(rat liver fractions (Tatsumi et al. 1981; Abraham et al. 1984; Vroomen et al, in 
press) and Escherichia coli (Abraham et al., 1984). In preliminary experiments we 
obtained evidence for the presence of this open chain cyano-derivative in plasma of 
piglets as well. Further studies presently are being undertaken to obtain more 
information concerning the identity and kinetics of metabolites of furazolidone in blood 
and tissues of swine. 
It also appeared that considerable amounts of the radioactivity in liver, kidney and 
muscle could not be extracted from the tissues after several consecutive extraction 
procedures. Persistent radioactivity might be covalently bound as is shown for other 
compounds, like the nitro imidazole compound ronidazole after administration to swine 
(Wolf et al. 1983). Also non-extractable radioactivity might be covalently bound as 
described for trenbolone-acetate (Ryan and Hoffmann 1978) and cambendazole (Baer 
et al. 1977) in cattle tissues and for 14C-toluoylchloride phenyl hydrazone in erythro-
cytes of sheep (Jaglan et al. 1977). 
Covalent binding may be the result of: 
(1) Activation to highly reactive intermediates which may covalently bind to 
biological macromolecules such as proteins, DNA or lipids. In the case of 
furazolidone such intermediates may be formed after reduction of the nitro group. 
The nitroso and N-hydroxylamino derivatives formed may covalently bind to 
macromolecules (Olive 1978; Swaminathan and Lower 1978). In vitro covalent 
binding of furazolidone to microsomal protein has been reported (Abraham et al. 
1984; Vroomen et al. in press) and for other nitrofurans to protein and DNA 
(Mattammal et al. 1985; Tatsumi et al. 1977). The possible role of the nitroso 
or N-hydroxylamino derivatives can be shown by trapping the reactive inter-
mediates with nucleophilic agents such as glutathione. A glutathione conjugate 
has been described for the nitrofuran N-[4-(5-nitro-2-furyl)2-thiazolyl]acetamide 
(Mattammal et al. 1985). 
(2) Metabolic degradation to non-drug related common carbon fragments, 
which may be incorporated in cellular components which are formed in various 
normal synthesis reactions. In the case of furazolidone metabolism the formation 
of a-ketoglutaric acid has been described as a result of degradation of the furan 
moiety of furazolidone in rats (Tatsumi et al. 1984). The formation of a-
ketoglutaric acid may occur after splitting of the furan moiety from 
the oxazolidone moiety. Such a cleavage may occur by hydrolysis under 
acid conditions (Paul et al. 1960), which are present in the stomach. a-Ketoglutaric 
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acid may be involved in several processes, but may also be catabolized to C0 2 
(Lehninger 1971). Tennent and Ray (1971) reported that 3% of total dosed 
radioactivity was detected in the expired air of rats after oral dosing of formyl 14C-
furazolidone. This radioactivity may be the result of formed 1 4C02 or volatile 
metabolites. In our study with piglets no radioactivity could be measured in the 
expired air, which may be expected in the case of formation of volatile metabolites. 
Detection of 14C02 formed by degradation of the furan moiety was not possible 
because 14C-furazolidone was labelled in the oxazolidone moiety. No data are 
available concerning metabolic degradation of the oxazolidone moiety to 
components which may be involved in normal anabolic or catabolic processes. 
Further studies are necessary to elucidate the molecular basis of cellular drug 
interactions. 
The in vivo interaction of 14C-furazolidone with DNA in tissues of piglets has been 
shown in this study. The interaction with DNA was especially marked in pancreas and 
kidney. In comparison for example the extent of binding to DNA of benzo(tf)pyrene in 
mice after an oral dose of 2 x 3 mg per animal varied from 177 — 230pmol per mg 
DNA in liver and from 22-32 pmol per mg DNA in lung (Anderson et al. 1981). After 
the withdrawal period of 14 days radioactivity could still be measured in the DNA 
isolated from the several tissues. Taking into account the growth of the piglets, it seems 
that during a 14 days withdrawal period there are no signs of a quick and effective 
DNA-repair mechanism in piglets for the DNA-damage caused by furazolidone. 
Mutagenic activity of furazolidone has been described in many prokaryotic test 
systems (Ohta et al. 1980; Blijleven et al. 1977; Kramers 1982; Voogd et al. 1982) and 
in eukaryotic systems (Cohen and Sagi 1979; Babile et al. 1978; Probst et al. 1981; 
Voogtetal. 1982). 
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ABSTRACT 
1. A sensitive method for the determination of 3-(4-cyano-2-oxobuty-
lidene amino)-2-oxazolidone, the open-chain cyano-derivative of the 
veterinary drug furazolidone, in swine plasma and tissues is described. 
2. After dosing adult swine orally with furazolidone (690 mg/ animal 
per day) for 10 days no furazolidone was detected in liver, kidney and 
muscle (< 2 ng/g). The half life of furazolidone as measured from the 
terminal phase of the plasma curves was 45 minutes. 
In urine small amounts (< 0.3% of total dose) of furazolidone were 
detected. 
3. The cyano-derivative of furazolidone, 3-(4-cyano-2-oxobutylidene 
amino)-2-oxazolidone is a minor metabolite in plasma and tissues of 
swine with a plasma half life of 4 h. No cyano-derivative was detected 
in liver and kidney (< 5 ng/g) 2 h after the last administration of 
furazolidone; 24 h after the last administration, the concentration in 
plasma was < 2 ng/ml and in muscle < 5/g. 
4. The cyano-derivative was not mutagenic in the Salmonella/microscome 
test, with or without metabolic activation. 
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INTRODUCTION 
Furazolidone [N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone] is a 
veterinary drug widely used as an antimicrobial agent for prophylactic 
and therapeutic purposes in swine (Brander and Pugh, 1971; Rossoff, 
1974). Because of its mutagenic and carcinogenic activities (Klemencic 
and Wang, 1978; McCalla, 1983; Food and Drug Administration, 1976) its 
use is of public health concern. Earlier studies showed that no resi-
dues of furazolidone could be detected in edible tissues, 2-4 hours 
after dosing (Winterlin et al., 1984; Vroomen et al., 1986a). 
However, up to 14 days after dosing, radioactivity of the order of 
ug-equivalents per gram could still be detected in tissues of piglets 
after oral administration of l^C-furazolidone (Vroomen et al., 1986a). 
No information is available concerning the identity, depletion kine-
tics and toxicity of metabolites of furazolidone in swine tissues. 
However, reduction of the nitro group, resulting in the formation of 
an open-chain cyano-derlvatlve, is an important metabolic pathway of 
nitrofurans (Swaminathan and Lower, 1978). No analytical method is 
available for the determination of the cyano-derivatlve of furazoli-
done in plasma and tissues. 
In this paper a sensitive HPLC-method is described for the determina-
tion of 3-(4-cyano-2-oxobutylidene amino)-2-oxazolidone the cyano 
derivative of furazolidone in plasma, muscle, liver and kidney of 
swine. The method showed its value in a study of the rate of 
disappearance of furazolidone and its open-chain cyano-derivative from 
plasma and tissues upon oral administration of furazolidone for 10 
days to swine. 
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Figure 1: Furazolidone (A) and its open-chain cyano-derivative (B). 
EXPERIMENTAL 
Chemicals and solvents 
L-asparagine, ethyl acetate and acetonitrile were purchased from Merck 
(Darmstadt, F.R.G.) and dextrose was purchased from Difco Laboratories 
(Detroit Michigan, U.S.A.). Water was purified over a Millipore Milli-
Q water purification system. Furazolidone was a gift from Orphahell 
B.V. (Mijdrecht, The Netherlands). 
Biosynthesis of the cyano-derivative of furazolidone using E.coli 
The cyano-derivative of furazolidone, 3-(4-cyano-2-oxobutylidene 
amino)-2-oxazolidone (figure 1), was synthezised using E. coli 
according to Abraham (1981) with several modifications. 
After an incubation period of 75 min at 37°C, the aqueous layer con-
taining E.coli was extracted twice with equal volumes of ice-cold 
ethyl acetate. The ethyl acetate extracts were combined and gently 
evaporated to dryness under vacuum. The resulting residue was 
dissolved in acetonitrile/ water (20/80). Separation of the cyano-
derivative was achieved on a semi-preparative Hibar prepacked column 
RT 250-10 Lichrosorb RP-18 (7 um) (Merck 50994) using a linear 22 min 
gradient of 2% - 100% actonltrile in water/acetonitrile (975/25) at a 
flow rate of 4 ml per min. The eluent was monitored at 254 nm. The 
fractions with the cyano-derivative (retention time 6.2 - 6.8 min) 
were collected and after evaporation to dryness under vacuum and 
redissolving in acetonitrile/water (20/80), the cyano-derivative was 
Isocratically chromatographed four times (water-acetonitrile 92/8, 
retention time: 10.4 - 11.0 min). White crystals were obtained with 
similar spectral properties as described earlier for a metabolite of 
furazolidone which was identified as 3-(4-cyano 2-oxobutylidene amino) 
-2-oxazolidone (Tatsumi et al., 1978; Abraham et al., 1984; Vroomen et 
al., 1987); characteristics of the mass spectrum (field desorption, 
m/z): 195 (molecular ion) and of the infra red spectrum in KBr (cm - 1): 
2250: cyano-group, 1778: oxazolidone, C=0 and 1688: a,(3 unsaturated 
C=0 stretching. 
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Analysis of the cyano-derivative 
Sample preparation 
Plasma. A 1-ml aliquot of plasma was applied directly to a Merck 
ExtrelutR 1 column (Merck 15371) and after equilibration for 10 min, 
the cyano-derivative was eluted with 6 ml of ethyl acetate. The eluate 
was collected, evaporated to dryness under nitrogen and the residue 
dissolved in 300 ul of eluent. 
Muscle. A 1-g frozen sample (liquid nitrogen) was pulverized and mixed 
with 4 ml of water for 2 min. After centrifugation at 3000 g for 15 min 
the water-extracts were applied to a Merck Extrelut^ 3 column (Merck 
15372) and after 10 min equilibration, the cyano-derivative was eluted 
with 15 ml of ethyl acetate. The eluate was collected, evaporated to 
dryness under nitrogen, the residue dissolved in 300 ul of eluent and 
ult'raf iltered (Amicon Centrifree Micropartition System) . No specific 
absorption of the cyano-derivative to the membrane occured. The ultra-
filtrate was subjected to HPLC. 
Kidney, liver. Quantities of 1 g of kidney and liver were prepared as 
described for muscle. Direct HPLC-analysis on a Hamilton PRP-1 column 
(see High Performance Liquid Chromatography, plasma and muscle) was 
not possible because of interference of other peaks absorbing at 
254 nm. Therefore a first separation was achieved on a Hamilton PRP-1 
column (250 x 4.1 mm int.diam.; 10 urn) using a linear 22 min gradient 
of 2% - 100% acetonitrile in water/acetonitrile (975/25) at a flow 
rate of 1 ml per min (injection volume: 150 ul). The fraction with the 
cyano derivative (retention-time: 11.5 - 12.3 min) was collected and 
after evaporation to dryness under nitrogen, the residue was dissolved 
in 300 ul of water/acetonitrile (80/20) and prepared for HPLC. 
High-performance liquid chromatography 
Liquid delivery system: Waters 6000 A; automatic injection system: 
Waters 710 B; detector: Kratos Spectroflow 773; absorbance was recorded 
at 254 nm; recorder: Kipp BD 41. 
Plasma and muscle. Analytical column: Hamilton PRP-1 (250x4.1 mm 
int.diam.; 10 um), precolumn: Brownlee Labs OD-GU RP-18 (30x4.6 mm 
int.diam.). Run-time: 17 min (after 5 min isocratic HPLC 
(water-acetonitrile, 75/25, v/v), the column was washed with water-
acetonitrile, 50/50 (v/v) for 12 min; flow-rate 1 ml/min; injection 
volume: 25 - 100 ul. Retention time: 4.3 - 4.8 min. 
Kidney and liver. Analytical column: Chrompack Hypersil 0DS 5 (250 x 
4.6 mm int.diam.) Precolumn: Brownlee Labs OD-GU RP-18 (30 x 4.6 mm 
int.diam.). 
Eluent: water-acetonitrile (80/20, v/v); flowrate: 1 ml/min; injection 
volume: 50-100 ul; run-time: 10 min. Retention time: 4.9 - 5.6 min. 
Analysis of furazolidone 
Analytical procedures were performed under artificial yellow light 
(Pope FT 40 W/16), because of the instability of furazolidone in 
daylight (Kalim, 1985). The concentration of furazolidone in blood, 
plasma, urine, liver, kidney and muscle was analysed as described 
elsewhere (Vroomen et al., 1986b). 
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Animal handling and sample collection 
Twelve male pigs (Dutch Landrace x Great Yorkshire; mean weight + 
S.D.: 89.3+3.6 kg) were Individually housed in metabolism cages at 
IGMB/TNO- Department ILOB, Wageningen, The Netherlands. After an 
acclimatization period of 1 week, the animals were divided into 2 
groups: 
Group I : 2 control animals 
Group II: 10 animals treated with furazolidone during 10 days. 
A standard swine diet without antibiotics was provided to group I 
twice daily at 9.00 h and 16.00 h. For group II furazolidone was added 
to the feed in a final concentration of 300 mg per kg. 
The daily amount of feed corresponded to the amount of feed under 
practical conditions: 2300 g/ animal per day. 
The feed/water ratio was 1:2. 
Urine was collected separately into containers to which an 1.0 M ace-
tate buffer (pH 5.0) was added. Each morning, just before feeding time 
at 9.00 h, total amounts of urine were measured and immediately 
samples were taken for analysis of the concentration of furazolidone. 
No blood samples were taken during the medication period, since ear-
lier studies Indicated a relatively short half life of furazolidone 
(Vroomen et al., 1986a) and the cyano-derivative (data not published) 
in plasma. 
After the last administration of furazolidone on day 11 at 9.00 h, 
blood samples were collected in heparinized tubes at regular time 
intervals from the jugular vein. Plasma was separated by centrifuga-
tion. Samples were immediately analysed for the concentration of fura-
zolidone since a time-dependent decrease of furazolidone in blood has 
been reported (Veale and Harrington, 1982). Plasma samples for the 
analysis of the cyano-derivative were stored at -40°C. 
On day 0, 1, 3, 7 and 14 of the withdrawal period, 2 animals of Group 
II were killed 2 h after feeding at 9.00 h. The animals of Group I 
were killed on day 0 and 14 of the withdrawal period, also at 11.00 h. 
Samples were taken of the liver, kidney and muscle for analysis of the 
concentration of furazolidone and the cyano-derivative, immediately 
frozen and stored at -40°C. 
Salmonella/microsome-test 
The Salmonella/microsome test was carried out as described by Haron 
and Ames (1983) using tester strains TA 98 and 100. 
Furazolidone and the cyano-derivative were tested dissolved in DMS0 in 
quantities of 0.01, 0.1, 1.0 and 10 yg, respectively 10 and 100 ug per 
plate, both in the presence and absence of 50 yl S9~mix (from livers 
of Aroclor-treated rats) per plate. 
RESULTS 
Determination of 3-(4-cyano-2-oxobutylidene amino)-2-oxazolidone 
The cyano-derivative of furazolidone as synthesized by E.coli was 
stable for at least one month in the range of 1 - 1000 ng/ml standard 
solution, when stored in the dark at room temperature. 
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MINUTES 
Figure 2: High-performance liquid chromatogram of the cyano-derivative 
in samples of swine muscle (A: blank, B: 10 ng/g cyano-
derivative) and swine liver (C: blank, D: 10 ng/g cyano-
derivative). (A,B) : X = 254 nm; speed 1 cm/min; sensitivity 
of detector: 0.01 aufs; sensitivity of recorder: 10 mV; 
injection volume: 50 ul. (C,D): A 254 nm; speed 1 cm/min; 
sensivity of detector: 0,002 aufs; sensitivity of recorder: 
10 mV; injection volume: 50 ul (M = the cyano-derivative of 
furazolidone). 
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Concentrations of the cyano-derivative of furazolidone were calculated 
by comparing the peak heights from samples to which the derivative had 
been added with the peak heights from corresponding standard solutions, 
containing the same amounts of cyano-derivative. Linearity exists 
between the concentration of the cyano-derivative and peak height in 
the range of 1 - 1000 ng/ml standard solution. Linearity was also 
found for samples. In blank samples of swine plasma, liver and kidney 
no interfering peaks could be detected at 254 nm. Despite of an inter-
fering peak in samples of swine muscle (figures 2A and 2B), the repro-
ducibility of the separation at all tested levels was not influenced, 
so the additional HPLC-separation step as described for liver and kid-
ney was not necessary. Recovery data for swine samples with added 
cyano-derivative of furazolidone in a concentration range of 1 - 1000 
ng/ml (or ng/g) of sample are shown in Table 1. 
Table 1: Percentage recoveries of the cyano-derivative of furazolidone 
from pig plasma and tissues. The cyano-derivative was added 
to pig plasma and tissues in a concentration range of 
0 - 1000 ng/ml or ng/g of sample (n = 6; mean + S.D.) 
Cyano-
derivative 
added 
(ng/g or 
ng/ml) 
1000 
100 
50 
25 
10 
% Recovery of cyano-derivative 
Plasma 
93.0 + 3.7 
104.1 + 4.2 
98.1 + 6.0 
97.4 + 3.1 
97.8 + 4.5 
Muscle 
97.7 + 3.6 
95.3 + 3.9 
89.1 + 3.1 
96.2 + 2.1 
92.5 + 8.1 
Liver 
70.3 + 5.8 
73.2 + 7.8 
71.0 + 9.7 
66.2 + 7.1 
72.4 + 6.9 
Kidney 
73.9 + 7.8 
67.5 + 2.3 
69.5 + 6.8 
76.7 + 8.9 
74.5 + 5.9 
Each result represents the average of six determinations. The mean 
overall recovery for plasma (n = 30) is 98.1 + 5.5, muscle (n = 30): 
94.2 + 5.1, liver (n = 30): 70.6 + 7.4 and kidney (n = 30): 72.3 + 
7.0). 
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The sensitivity of the method, expressed as three times the background 
of a blank sample was 2 ng/ml for plasma, 5 ng/g for muscle, liver and 
kidney of swine. 
In figure 2, the chromatograms of a blank and a muscle sample (10 ng/g) 
and a blank and a liver sample (10 ng/g) are shown. 
Kinetic studies 
Plasma. Neither furazolidone nor the cyano-derivative could be detected 
in plasma samples taken just prior to the last administration of fura-
zolidone on day 10. Mean plasma levels of furazolidone and the cyano-
derivative after the last oral administration are shown in figure 3. 
The concentration of furazolidone reached maximum levels of 62-121 
ng/ml within 60-75 min after administration while similar values were 
observed in blood. Elimination half life of furazolidone as measured 
from the terminal phase of the plasma curves was approximately 45 min. 
The concentration of the cyano-derivative reached maximum levels of 
24.9-45.3 ng/ml within 90-240 min after administration. Seventeen h 
after administration the concentration was < 2 ng/ml. 
Urine. The mean total daily amounts of furazolidone excreted via the 
urine are shown in figure 4. Maximum excretion was measured after 
2 days of medication: 447-1784 ug of furazolidone per animal. In the 
following days of the medication period a decrease was observed. After 
10 days of medication the excreted amounts varied from 170-293 ug of 
furazolidone per animal. The daily amount of furazolidone excreted via 
the urine was only 0.06% + 0.04% (n=108) of the daily administered 
dose of furazolidone with an individual maximum of 0.26% and a minimum 
of 0.01%. 
Within 5 h after the last administration more than 60% of the total 
excreted amount was excreted via the urine; 24 h after the last admi-
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TIME AFTER LAST ADMINISTRATION (HOURS) 
Figure 3: Mean plasma levels of furazolidone and its cyano-derivative 
(ng/ml) after the last oral administration of furazolidone 
to swine (n=10, after t=2 h n=8). Furazolidone: • • , the 
cyano-derivative: -•—• • 
1000--
500- -
K. 
10 
TIME OF TREATMENT (DAYS) 
Figure 4: Mean total daily amounts of furazolidone (ug) excreted via 
the urine (n=10) during the medication period. 
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nistration no more furazolidone could be detected in urine (< 25 ng/ml) 
(data not shown). 
Muscle, liver and kidney. None of the animals showed abnormalities at 
autopsy. Furazolidone could not be detected in muscle, liver and kid-
ney of adult swine (< 2 ng/g tissue) 2 h after the last administration 
of furazolidone on day 10. The cyano-derivative could only be detected 
in muscle of swine, killed 2 h after the last drug administration: 
mean level (n=2): 17 ug/kg muscle. 
Mutagenicity test with Salmonella typhimurium. 
Furazolidone was positive with TA 100 at all tested concentrations, 
while a dose-effect relation was observed. The addition of 50 ul 
Sg-mix did not influence the results (data not shown). The cyano-
derivative was negative at doses up to 0.1 mg per plate for both TA 98 
and 100, with and without metabolic activation. 
DISCUSSION 
In earlier studies half lives of furazolidone in plasma after oral 
treatment varied from 27 min for pigs weighing 30-40 kg (1000 mg fura-
zolidone per kg feed) (Yamamoto et al., 1978) to 60 min for piglets 
weighing approximately 10 kg (300 mg furazolidone per kg feed) (Vroomen 
et al., 1986 a). Differences in half life may be explained by the 
fact that the biotransformation capacity and the renal clearance func-
tion is in general less developed in younger animals. Short et al. 
(1972) reported that the rate of nitroreduction of p-nitrobenzoic acid 
in liver of swine increased from 655 nmol per g of tissue for a 6 week 
old piglet to 905 nmol per g of tissue for an adult swine. 
Furazolidone inhibits the growth of Gram-negative and Gram-positive 
pathogenic bacteria in a minimal concentration range of 1-10 ug per ml; 
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however, for Proteus species and Pseudomonas aeruglnose minimal con-
centrations up to 300 ug per ml are necessary (Van Esch et al., 1983). 
Since the concentration of furazolidone reached maximum plasma levels 
in adult swine of 60-120 ng/ml after oral administration through feed 
in a concentration of 300 mg/kg, it may not to be effective against 
other than gastrointestinal infections, as also has been observed for 
the piglet (Vroomen et al., 1986a). 
No furazolidone could be detected in liver, kidney and muscle 2 h 
after stopping the medication. Comparable results have also been 
reported in studies with piglets (Vroomen et al., 1986a), swine and 
poultry (Winterlin et al'., 1984). 
In earlier studies it has been shown that urine is the main excretion 
pathway; after oral administration of ^C-furazolidone to the piglet, 
barrow or rat respectively 61%, 70.5% and 81.5% of total dosed 
radioactivity was recovered in urine (Vroomen et al., 1986a; Tennent 
and Ray, 1971). The percentage of unchanged furazolidone excreted via 
the urine was not determined in these studies. 
From this study it appears that only a small fraction of the total 
administered dose was excreted via the urine as unchanged furazolidone 
(0.01-0.26%), apparently due to effective biotransformation. 
After 2 days of medication a decrease in the concentration of the 
parent compound excreted via the urine was observed, indicating that 
specific metabolizing enzymes may have been induced. Detailed infor-
mation concerning the identity, depletion kinetics and toxicity of 
formed metabolites is necessary for the evaluation of the risk of 
residues of drugs used in food-producing animals for human. 
Reduction of the nitro group is a major metabolic pathway of nitro-
furans (Swaminathan and Lower, 1978). The open-chain cyano-endproduct 
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of reductive metabolism of furazolidone, 3-(4-cyano-2-oxobutylidene 
amino)-2-oxazolidone, appeared to be an important metabolite in rats 
(Tatsumi et al., 1984), rat liver fractions (Tatsumi et al., 1981; 
Abraham et al., 1984; Vroomen et al., 1987), eels (Nakabeppu and 
Tatsumi, 1984) and Escherichia coli (Abraham et al., 1984). The cyano-
derivative of furazolidone could also be detected in the urine of 
rabbits after oral treatment (Tatsumi et al., 1978). 
From this study it appears that the cyano-derivative is a minor meta-
bolite of furazolidone in swine after oral administration. This may be 
the result of different species specific metabolic pathways of furazo-
lidone in swine. Several other pathways have been postulated for 
nitrofurans: hydroxylation of the furan ring in the 4- position or 
oxidation of the side chain (Swaminathan and Lower, 1978), hydrolysis 
of the azomethine binding, (Schmid, 1985) and for methylfurans epoxi-
dation of the furan ring (Ravindranath et al., 1984). Another explana-
tion may be a very fast elimination of the cyano-derivative via the 
urine. Also effective trapping of reactive intermediates of furazoli-
done such as nitroso and N-hydroxylamino-derivatives by biological 
macromolecules or agents like glutathione may occur (Olive, 1978; 
Swaminathan and Lower, 1978). Covalent binding of furazolidone with 
protein and DNA in vivo has been reported in piglets (Vroomen et al., 
1986a). A glutathione dependant covalent binding of furazolidone to 
rat liver microsomal protein in vitro has been reported (Vroomen et 
al., 1987). Mutagenicity of furazolidone is probably also due to 
reductive activation to nitroso or hydroxylamino derivatives which may 
react with DNA rather than to the activity of the unmetabolized com-
pound. Once reduced to stable endproducts, mutagenic activity becomes 
unlikely (Rosenkranz and Speck, 1976; Klemencic and Wang, 1978; 
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McCalla, 1983). This is supported by results of studies performed by 
Tatsumi et al. (1978) and our laboratory showing that the reductive 
endproduct, the open-chain cyano-derivative, was not mutagenic in the 
Ames test both with or without metabolic activation. 
In conclusion these studies underline the importance of detailed meta-
bolism studies of drugs in the proper target animals. Furazolidone is 
rapidly degraded in swine and not detectable in edible tissues after 
oral administration. The cyano-derivative which is a major metabolite 
in several animals, is only a minor metabolite in plasma and tissues of 
swine. Furthermore from studies with piglets dosed with l^C-furazo-
lidone it is known that radioactivity in the order of ug-equivalents 
per gram of tissue could be detected. Therefore extensive biotransfor-
mation of furazolidone must take place in swine. No further informa-
tion concerning the identity, depletion kinetics and toxicity is 
available on metabolites present in edible tissues of swine after oral 
treatment with furazolidone. Further studies are in progress which may 
serve as a basis for a proper risk estimation of the application of 
furazolidone to swine in relation to human health. 
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Abstract—The nitrofuran, furazolidone, is metabolized by rat liver microsomes under both aerobic and 
anaerobic conditions, the rates for microsomes from 3-methylcholanthrene-induced male rats being 3.52 
and 4.26nmol/mg protein/min, respectively. The two major metabolites formed are the well-known 
3-(4-cyano-2-oxobutylideneamino)-2-oxazolidone, and 2,3-dihydro-3-cyanomethyl-2-hydroxy-5-nitro-
la,2-di-(2-oxo-oxazolidin-3-yl)iminomethylfuro[2,3-6]furan (accounting for 16.6 and 16.4% of total 
extractable radioactivity, respectively). Cytochrome iM50 is not involved in the conversion of fura-
zolidone, which was converted by rat liver microsomes to products identical to those obtained upon 
incubation with purified NADPH-cytochrome P-450 reductase, which is a microsomal reductase. During 
metabolism, a considerable amount of material (2-3% of total metabolites) became covalently bound to 
microsomal protein. This covalent binding could be inhibited by addition of glutathione, which also 
resulted in an almost complete shift from non-polar to water-soluble metabolites. No interaction of 
furazolidone with added calf thymus DNA was detected. 
INTRODUCTION 
Furazolidone (iV-(5-nitro-2-furfurylidene)-3-amino-
2-oxazolidone) is an antimicrobial veterinary drug, 
widely used for the therapy and prevention of intes-
tinal infections in pigs, poultry and cattle. It is 
mutagenic (Klemencic & Wang, 1978; McCalla, 
1983) and appears to be carcinogenic (Food & Drug 
Administration, 1976 & 1984). 
After oral administration of furazolidone to pigs 
the concentration of the drug in edible tissues was 
below the limit of detection (0.5/jg/kg tissue) within 
4hr of the last administration (Wintertin et al. 
1984). However, radioactive material corresponding 
to approximately 2 ppm-equivalents of parent com-
pound could be detected in the tissues 14 days after 
treatment of piglets with [14C]furazolidone was 
stopped (Vroomen et al. 1985). A major part of the 
residual radioactivity was non-extractable (Vroomen 
et al. 1986). 
Information on the toxicity of residual metabolites 
of furazolidone in animal products with regard to 
human health is limited, and covalently bound resi-
dues are of particular interest in this respect. There-
fore, a quantitative and qualitative study of the 
process of covalent binding of furazolidone to biolog-
ical macromolecules seemed indicated. 
Abbreviations: GSH = glutathione; HPLC = high-pressure 
liquid chromatography; 3MC = 3-methylcholanthrene; 
PB = phenobarbital; TLC = thin-layer chromatography. 
Reduction of the nitro group is a major metabolic 
pathway of nitrofurans (Swaminathan & Lower, 
1978). Previous studies have identified several 
metabolites of reductive metabolism both in vitro 
and in vivo. The cyano derivative 3-(4-cyano-2-
oxobutylideneamino)-2-oxazolidone appeared to be 
the major end product of reductive metabolism of 
furazolidone (Abraham et al. 1984; Nakabeppu & 
Tatsumi, 1984; Tatsumi et al. 1978, 1981 & 1984). 
Reduction of the nitro group may result in the 
formation of reactive intermediates, which may cova-
lently bind to biological macromolecules such as 
protein and DNA (Swaminathan & Lower, 1978). 
As a possible model for in vivo metabolism, 
we describe in this paper the in vitro aerobic and 
anaerobic metabolism of furazolidone by rat liver 
microsomes and the compound's interaction with 
microsomal protein and added calf thymus DNA, 
MATERIALS AND METHODS 
Chemicals. [l4C]Furazolidone was a gift from Nor-
wich Eaton Pharmaceuticals Inc., Norwich, NY, 
USA. It was labelled in the methylene groups of the 
oxazolidone moiety (specific activity, 2.69^Ci/mg; 
radiochemical purity >99% by TLC (toluene-acetic 
acid-acetone-water, 600:240:80:25, by vol.) and 
HPLC). The counting fluids used were Minisolve 
(Zinsser Analytic (UK) Ltd, Maidenhead, Berks.) 
and Dimilume-30* (Packard Instrument BV, Delft) 
for aqueous and non-aqueous samples, respectively. 
NADPH, glucose-6-phosphate and glucose-6-
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phosphate dehydrogenase were obtained from Boeh-
ringer Mannheim GmbH, Mannheim, FRG. DNA 
(calf thymus, type 1) and reduced glutathione (GSH) 
were purchased from Sigma Chemical Co., St Louis, 
MO. NADPH-cytochrome-/M50 reductase (purifi-
cation and measurement of activity carried out ac-
cording to Yasukochi et al. 1979) was kindly supplied 
by Dr P. Bonants of the Department of Biochemistry 
of the Agricultural University, Wageningen. All the 
other chemicals used were of reagent grade. 
Preparation of microsomes. Male Wistar rats were 
pretreated either with 3-methylcholanthrene (3MC), 
administered as three daily ip injections each of 
30mg/kg body weight, or with phenobarbital (PB) 
given over 7 days at a level of 0.1 % in the drinking-
water. An untreated group served as the control. 
Livers were perfused with a 20mM-Tris HC1, 
250 mM-sucrose buffer (pH 7.4), homogenized in a 
teflon Potter-Elvehjem homogenizer and centrifuged 
for 20 min at 9000 g. The supernatant (S-9 fraction) 
was centrifuged for 90 min at 105,000 g. After the 
supernatant (cytosolic fraction) had been decanted, 
the microsomal pellet was washed in 150 mM-KCl 
and then resuspended in lOOmM-potassium phos-
phate buffer, pH 7.4. The S-9 fraction, cytosol and 
microsomes were all stored at — 25°C. Protein con-
centration was determined by the method of Lowry 
et at. (1951). 
Microsomal incubation. Unless stated otherwise, a 
standard incubation mixture was used containing 
1 mM-NADPH, 3mM-MgCl2, 0.1 M-potassium phos-
phate buffer, pH 7.4, and 1.46-2.95 mg protein. Incu-
bations were started by the addition of 50/d 
[14C]furazolidone dissolved in acetone (final concen-
tration, 36.7liM). The final volume was 2ml. After 
incubation for 5 min at 37°C the reaction was termi-
nated by the addition of 1 ml acetone. Non-polar 
metabolites were extracted with 4 x 2 ml ethyl ace-
tate. After evaporation of the ethyl acetate under 
nitrogen, the residue was dissolved in 300/jl 
acetonitrile-water, 30:70, v/v (I; representing the 
ethyl acetate fraction) and used for HPLC or radio-
activity measurements. After extraction with ethyl 
acetate, the protein in the aqueous phase was precip-
itated by the addition of ice-cold methanol. After 
centrifugation for 15 min at 1500g, the aqueous/ 
methanolic supernatant was decanted and evapo-
rated under nitrogen. The polar metabolites were 
dissolved in 300 jd acetonitrile-water, 30:70, v/v (II; 
representing the aqueous fraction) and were used for 
radioactivity measurements or HPLC. The precip-
itated protein was washed three times with methanol, 
twice with ethanol and twice with ether. The resulting 
pellet (III; representing the protein fraction) was 
dissolved in 1 ml Soluene 350 (Packard Instrument 
BV), incubated for at least 4 hr at room temperature 
and used for measurement of the radioactivity (the 
amount of radioactivity defined as originating from 
covalently bound residues). After the protein was 
washed with methanol, no more radioactivity could 
be extracted. Anaerobic conditions were achieved by 
shaking the incubation mixture for 3 min under a 
constant flow of argon, after which the incubation 
bottles were sealed. For incubations longer than 
5 min, an NADPH-regenerating system—10mM-
glucose-6-phosphate and 10 U glucose-6-phosphate 
dehydrogenase—was added to the medium. Calf thy-
mus DNA, added at 1 mg/ml of incubation mixture, 
was isolated as described elsewhere (Jeffreys & 
Flavell, 1977), dissolved in lOmM-Tris HC1, pH 7.5, 
and prepared for radioactivity measurements. In 
studies on the effect of GSH on microsomal metab-
olism of furazolidone, GSH was added to the incu-
bation mixture at levels of 0.5-10 HIM. Incubations 
with microsomes inactivated by heating or withoui 
NADPH served as controls. Incubations and all 
other procedures before HPLC analysis were per-
formed in the dark because of the photosensitivity of 
furazolidone in solution (Kalim, 1985). 
HPLC analysis. HPLC analyses were performed 
with a Perkin-Elmer Series 4 HPLC system. Sepa-
ration of the non-polar metabolites of furazolidone 
was achieved on a Chrompack Hypersil 5 ODS col-
umn (250 x 4.6 mm). After injection of 100/il of an 
incubation sample, all radioactivity (>99%) was 
eluted with a linear 22-min gradient of 2-100% 
acetonitrile in water-l.OM-acetate buffer pH 
5.0-acetonitrile (900:75:25, by vol.) at a flow rate of 
1 ml/min. The eluate was monitored at 254 nm and 
for radioactivity measurements 0.2 ml fractions were 
collected. After addition of 3 ml Minisolve, the 
amount of radioactivity was determined in a Philips 
liquid scintillation counter (type PW 4700). Counting 
efficiency was calculated by means of an external 
standard counting procedure. The data presented in 
this paper are representative of at least three experi-
ments. The experimental variation was within 10%. 
Identification of non-polar metabolites of fura-
zolidone. For identification of the non-polar metabo-
lites of furazolidone, aliquots of fraction I (see earlier) 
were chromatographed as described above. Ultra-
violet (UV) absorption spectra were obtained with a 
Hewlett-Packard photodiode array detection system 
(detector 1040 A, diskdrive 9121, computer 85B and 
plotter 7470A). Infrared (IR) spectra of the various 
compounds in 5 mg KBr were recorded on a Bruker 
IFS-85 instrument with diffuse reflectance techniques. 
Proton nuclear magnetic resonance (NMR) spectra 
of furazolidone or its metabolites dissolved in CDC13 
were obtained with a Bruker CXP 300. Mass spectra 
were obtained with an AEI MS 902 mass spectro-
meter coupled to a VG-ZAB console. 
Analytical data 
Chromatographic analysis of fraction I (the ethyl 
acetate extract of the product of microsomal metab-
olism of furazolidone) revealed four major peaks— 
A, B, V and furazolidone (Fig. 1). When the same 
reversed-phase HPLC method was used for samples 
of fraction II, most (>85%) of the radioactivity 
appeared at the solvent front, indicating the high 
polarity of the compounds in that fraction. With 
fraction I, peak A appeared with the solvent front. 
There are indications of at least three different radio-
active substances in that peak but they have not yet 
been clearly identified. 
Characteristics of metabolites B and C are shown 
in Table 1. The double doublet at S 4.83 in the NMR 
spectrum of metabolite C (Fig. 2) coupled with the 
doublet at S 5.85 and a proton in the multiplet at <5 
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Time (min) 
Fig. 1. HPLC analysis of metabolites (A, B and C) of 
[l4C]furazolidone (F) present in the ethyl acetate extract 
after microsomal incubation under aerobic conditions. 
3.89. This proton at S 3.86 also coupled with the 
doublet at d 2.35. Coupling was proved by using spin 
decoupling methods. 
In vitro metabolism of furazolidone 
The in vitro aerobic metabolism of furazolidone by 
liver microsomes from 3MC-induced male rats is 
characterized by rapid conversion of the parent com-
pound. After a 5-min incubation period, 36.1% of 
furazolidone was converted, of which 44.2% was 
located in the ethyl acetate extract and 52.9% in the 
aqueous phase, while 2.9% was associated with pro-
tein (Table 2). Two major metabolites (B and C) were 
isolated from the ethyl acetate extract (Fig. 1). Char-
acteristics similar to those found for metabolite B 
(Table 1) have been described earlier for a fura-
zolidone metabolite which was identified as 
3 - (4 - cyano - 2 - oxobutylideneamino) - 2 - oxazolidone 
(Fig. 3), the open-chain cyano derivative (Abraham 
et al. 1984; Tatsumi et al. 1978). The UV, IR and 
NMR spectra of metabolite C showed great similarity 
to the spectra of a product of furazolidone obtained 
after in vitro metabolism using milk xanthine oxidase 
and rat liver 9000-g supernatant (Tatsumi et al. 1981). 
This reduction product was tentatively identified 
by the authors as 2,3-dihydro-3-cyanomethyl-2-
hydroxy-5-nitro-a,2-di-(2-oxo-oxazolidin-3-yl)imino-
methylfuro[2,3-6]furan (Fig. 3). The doublet at <5 2.35 
(2H), which can be attributed to two methylene 
protons, is even more likely than a signal overlapped 
by a signal due to water at 5 3.34, as assumed by 
Tatsumi et al. (1981). 
The characteristics of the metabolism of fura-
zolidone by rat liver microsomes are shown in 
Table 2. Conversion of furazolidone at a rate of 
3.52nmol/mg protein/min was measured under 
aerobic conditions. The amount of material con-
verted was approximately 20% higher under anaer-
obic than under aerobic conditions. Microsomes of 
untreated male rats metabolized furazolidone at 
a slower rate than microsomes of 3MC-treated 
male rats (2.29 and 3.52 nmol/mg protein/min, 
respectively). There was no significant difference in 
conversion rates between microsomes of PB-induced 
and 3MC-induced male rats, but small differences in 
the relative amounts of the metabolites formed could 
be observed. An increase in the relative amount of 
metabolite B and a decrease in the relative amount of 
metabolite C were observed on increasing the incu-
bation time from 5 to 15 min. No further changes in 
the percentages of individual metabolites in the ethyl 
acetate extract were observed on increasing the incu-
bation time from 15 to 60 min (Table 2). 
The conversion of furazolidone is an enzymatic 
NADPH-dependent process, which is located in the 
microsomal fraction but is independent of cyto-
chrome /M50. Thus, no conversion of furazolidone 
was observed when the microsomes were inactivated 
by heating, or when NADPH was absent from the 
incubation mixture, indicating that NADPH-
dependent enzymes are involved in the metabolism of 
furazolidone by rat liver microsomes. Furthermore, 
the fact that no influence on the metabolism of 
furazolidone could be detected on saturation of the 
incubation mixture with carbon monoxide (Table 3) 
Table 1. Characteristics of metabolites B and C formed during microsomal metabolism of furazolidone 
Metabolite B Metabolite C 
UV spectrum, kmtx (nm) 
IR spectrum in KBr (cm -1) 
H-NMR in CDCIj (ppm) 
Mass spectrum (mjz) 
—field desorption 
—electron impact 
226, 268 
2250: cyano group 
1778: oxazolidone, C = 0 
1688: a, ^-unsaturated C = 0 stretching 
7.07, singlet (1H) 
4.64, triplet (2H) 
3.87, triplet (2H) 
3.33, triplet (2H) 
2.67, triplet (2H) 
195 (molecular ion) 
113, 82 (fragment ions) 
226, 275 
3207: hydroxyl group (Fig. 2) 
2247: cyano group 
1769: oxazolidone, C = 0 
1561: nitro group 
1358: nitro group 
7.43, singlet (1H) (Fig. 2) 
7.38, singlet (IH) 
5.85, doublet (IH) 
4 83, double doublet (IH) 
4.58, multiplet (4H) 
3.89, multiplet (5H) 
2.35, doublet (2H) 
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Fig. 2. (a) IR and (b) NMR spectra of metabolite C of furazolidone. 
indicated that cytochrome P-450 is not involved in 
the conversion of furazolidone by rat liver micro-
somes in vitro. Furazolidone was metabolized to 
some extent under aerobic conditions by the 9000-g 
rat liver fraction, but at a much lower rate 
(0.67 nmol/mg protein/min) than by the microsomal 
fraction, while the cytosolic fraction of rat liver 
hardly converted furazolidone at all (Table 3). 
A well known NADPH-dependent microsomal 
reductase is NADPH-cytochrome P-450 reductase 
(cytochrome c reductase). Purified cytochrome P-450 
reductase converted furazolidone under anaerobic 
conditions into the same metabolites as did the 
microsomes (Table 4). The conversion rate for the 
purified enzyme was 14.5 nmol/min/unit of reductase 
compared with a conversion rate for the microsomes 
(0.2 units NADPH-dependent cytochrome P-450 
reductase/mg protein) of 21.3 nmol/min/unit of re-
ductase (Table 2). No conversion by the purified 
enzyme could be measured under aerobic conditions 
(data not shown) or in the absence of NADPH 
(Table 4). 
Covalent binding of furazolidone to protein and DNA 
and the effect of glutathione 
Under standard aerobic incubation conditions, 
detected covalent binding of furazolidone to protein 
amounted to 0.52 nmol/mg protein (2.9% of total 
•metabolites). The amount of furazolidone associated 
with protein increased under anaerobic conditions 
and also with an increase in the amount of micro-
somal protein in the incubation mixture or with an 
increase in the incubation time (Table 2). No protein 
binding could be detected when the microsomes were 
inactivated by heating or when NADPH was absent 
from the incubation mixture (Table 2). Addition of 
calf thymus DNA (1 mg/ml) to the incubation mix-
ture did not influence the in vitro conversion of 
furazolidone by microsomes of male rats treated with 
3MC (Tables 2 & 5). No radioactivity was detected 
bound to DNA even after an incubation time of 
60 min. 
When GSH was added to the incubation mixture 
in a concentration of 2 mil or more, the metabolites 
B and C were not detected, but an increase in polar 
metabolites and a decrease in covalent binding to 
protein was observed (Table 5). Under anaerobic 
conditions the rate of total conversion was indepen-
dent of the addition of GSH, but under aerobic 
conditions a decrease in rate of up to 60% was 
observed. 
DISCUSSION 
Reduction of the nitro group is an important 
metabolic pathway for nitrofurans (Swaminathan & 
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Lower, 1978). Several metabolites of in vivo or in vitro 
reductive metabolism of furazolidone have already 
been identified (Abraham el al. 1984; Nakabeppu & 
Tatsumi, 1984; Tatsumi et al. 1978, 1981 & 1984). 
This report presents data that support the reductive 
metabolism of furazolidone in vitro: 
(1) The well-known 3-(4-cyano-2-oxobutyl-
ideneamino)-2-oxazolidone (metabolite B), the 
open-chain cyano derivative that has also been 
found in other biological systems such as rabbits 
(Tatsumi et al. 1978), eels (Nakabeppu & Tatsumi, 
1984), rats (Tatsumi et al. 1984), rat liver fractions 
(Abraham et al. 1984; Tatsumi et al. 1981) and 
Escherichia coli (Abraham et al. 1984), has been 
identified as an end product of the reductive 
metabolism of furazolidone. 
(2) In contrast to another study on the metabo-
lism of furazolidone by rat liver microsomes 
(Abraham et al. 1984), we found a second non-
polar metabolite (C). The characteristics of this 
metabolite show great similarity to the character-
istics of a reduction product of furazolidone 
obtained after in vitro metabolism using milk 
xanthine oxidase and rat liver 9000-g supernatant 
(Tatsumi et al. 1981). The presence of a cyano 
group in the IR spectrum indicates that this 
metabolite is the result of a process of fura-
zolidone reduction. When metabolite C was sepa-
rated from metabolite B and then redissolved in 
water, no metabolite B was detected by HPLC 
analysis, and similarly no metabolite C was de-
tected in an aqueous solution of isolated metabo-
lite B, indicating that no equilibrium exists 
between these two non-polar metabolites. Fur-
thermore the concentration ratio of the two non-
polar metabolites did not change on prolonged 
incubation (> 15 min), indicating that a common 
intermediate may precede the formation of both 
metabolites. 
(3) The nitro reduction may be catalysed by nitro 
reductases such as the microsomal enzyme 
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NADPH-cytochrome /M50 reductase (Gillette, 
1971). This is supported by the observation that 
the conversion of furazolidone under anaerobic 
conditions by purified NADPH-cytochrome P-
450 reductase resulted in the same end products as 
were obtained after anaerobic conversion by rat 
liver microsomes. Furthermore, the characteristics 
of this microsomal conversion of furazolidone are 
similar to the NADPH-cytochrome P-450 reduc-
tase activities demonstrated for the metabolism 
of several other nitrofurans (Boyd el al. 1979; 
Mattammal et al. 1985; Swaminathan & Lower, 
1978; Wang et al. 1974; Zenser et al. 1981). Under 
aerobic conditions, furazolidone is also converted 
by rat liver microsomes. Nitro reduction under 
aerobic conditions has been reported elsewhere for 
rat liver microsomes (Abraham et al. 1984) and 
isolated perfused rat liver (Bond et al. 1984). 
However no conversion under aerobic conditions 
could be measured in studies with purified 
NADPH-cytochrome P-450 reductase. The rea-
son for this difference is not known, but may be 
found in the re-oxidation of the initial product by 
oxygen (Gillette, 1971), a reaction that may occur 
more readily with the purified enzyme than when 
the enzyme is present in liver microsomes. 
Although PB, in contrast to 3MC, is an inducer of 
NADPH-cytochrome P-450 reductase (Gillette, 
1971; Wang et al. 1974) no difference in fura-
zolidone conversion under aerobic conditions was 
observed between microsomes from 3MC- and 
from PB-induced rats, indicating the possible in-
volvement of other NADPH-dependent enzymes 
that may be induced by 3MC-pretreatment of rats. 
This is supported by the observation that under 
anaerobic conditions the conversion rate for mi-
crosomes (nmol/min/unit of NADPH-dependent 
cytochrome /M50 reductase) was some 50% 
higher than the conversion rate for the purified 
enzyme. 
Reduction of the nitro group in nitrofurans is a 
multi-step process with two important 
intermediates—the nitroso derivative and sub-
sequently the hydroxylamine derivative (Swamina-
than & Lower, 1978; Fig. 3). These reactive inter-
mediates are believed to be responsible for the 
inactivation of susceptible bacterial strains (Asnis et 
al. 1952; Paul et al. 1952) and for the mutagenic and 
carcinogenic activities of some nitrofurans (Cohen, 
Table 4. In vitro anaerobic conversion of furazolidone (36.7 jiu) by purified NADPH-dependent cytochrome P-450 reductase 
Incubation 
time (min) 
0 
2 
5 
30 
30f 
30 
Specific -
conditions* 
Standard 
Standard 
Standard 
Standard 
T 
Without NADPH 
Main EtAc-soluble metabolites 
<% 
A 
ND 
12.6 
12.4 
13.7 
13.4 
ND 
of total metabolites in fraction I) 
B 
ND 
26.2 
27.4 
29.5 
33.2 
ND 
C 
ND 
32.7 
35.0 
33.6 
37.5 
ND 
Metabolites (% of 
total) in 
- 1 
(EtAc) 
ND 
15.9 
19.4 
24.8 
25.3 
ND 
fraction: 
11 
(water) 
ND 
84.1 
80.6 
75.2 
74.7 
ND 
(%) 
ND 
79.0 
88.7 
88.1 
84.5 
ND 
EtAc = Ethyl acetate ND = Not detectable 
•Cytochrome /M50 reductase was added throughout at 2 U/2 ml incubation mixture, 1 U being the amount of reductase that reduces 
1 /imol cytochrome c/min at 25nC. 
•flncubation for 15 min under anaerobic conditions followed by 15 min in an aerobic atmosphere. 
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1978; Klemencic & Wang, 1978). Reduction of aro-
matic nitro compounds to arylamines has been shown 
to occur via the same reactive intermediates in vivo 
and in vitro (Kriek & Westra, 1979). These nitroso 
and hydroxylamine derivatives of aromatic com-
pounds easily react with GSH (Dolle et al. 1980; 
Eyer, 1979; Eyer & Kampffmeyer, 1982; Eyer & 
Schneller, 1983; Mulder et al. 1982 & 1984). In the 
present study, it was found that the non-polar metab-
olites could not be detected upon addition of GSH, 
in concentrations at or above 2 mM, to the incubation 
mixture. Such an effect has also been described in 
E. coli systems (Abraham et al. 1984). In addition, 
the covalent binding of [l4C]furazolidone to protein 
decreased upon addition of GSH. These findings 
are probably the result of an interaction of the 
nitroso or hydroxylamine derivative of furazolidone 
with GSH. GSH conjugation has already been 
described for the nitrofuran Ar-(4-(5-nitro-2-furyl)-2-
thiazolyl)acetamide (Mattammal et al. 1985). Studies 
aimed at the elucidation of the structure of the 
protein adduct(s) in vitro and in vivo are being 
undertaken. 
The iV-hydroxy derivatives are the intermediates 
responsible for interaction with DNA after activation 
of aromatic amines and amides by Af-oxidation 
(Dolle et al. 1980; Eyer, 1979; Eyer & Kampffmeyer, 
1982; Eyer & Schneller, 1983; Kriek & Westra, 1979; 
Mulder et al. 1982 & 1984). In the study reported 
here, no interaction with calf thymus DNA was 
observed in vitro, in contrast to findings in vivo 
(Vroomen et al. 1986). Perhaps a difference exists 
between the in vitro and in vivo situation in the 
availability of hydroxylamine derivatives for reaction 
with DNA. 
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CHAPTER 6: Identification of a reactive Intermediate of furazolidone 
formed by swine liver microsomes 
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SUMMARY 
Furazolidone (N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone) is 
metabolized by swine liver microsomes under aerobic and anaerobic 
conditions (rate: 2.55 and 3.25 nmol per mg protein per minute respec-
tively). Covalent binding to microsomal protein amounted aerobically 
to 0.29 nmol per mg protein per minute. Of all amino acids tested, 
only addition of cysteine to the incubation mixture decreased micro-
somal protein binding of furazolidone, indicating that covalent 
binding may occur at protein thiol groups. Two known metabolites of 
furazolidone, 3-(4-cyano-2-oxobutylidene-amino)-2-oxazolidone and 2,3 
dihydro-3-cyanomethyl-2-hydroxyl-5-nitro-l a, 2-di(2-oxo-oxazolidin3-yl) 
iminomethyl-furo[2,3-b]furan, were minor metabolites. At least 50% of 
total metabolites is formed by swine liver microsomes via a reductive 
process of furazolidone as indicated by the formation of a furazoli-
done-mercaptoethanol conjugate after the addition of mercapto-ethanol 
to the incubation mixture. The conjugate was identified as 3-(4cyano-
3-3-hydroxyethylmercapto-2-oxobutylidene amino)-2-oxazolidone, indi-
cating that the open-chain acrylonitrile-derivative is the reactive 
intermediate of furazolidone which also may be responsible for inter-
action with protein. 
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INTRODUCTION 
Furazolidone (N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone) is a 
nitrofuran widely used as an antimicrobial agent in veterinary practice. 
Because of its mutagenic and carcinogenic properties (1,2) residues 
should be avoided in edible tissues of animals treated with the drug. 
In the case of treatment of swine with furazolidone, no furazolidone 
could be detected 2-4 hours after terminating a prolonged treatment 
(3,4). However, using [14c]-furazolidone it was shown that radio-
activity at yg-equivalents of parent compound per gram of tissue could 
be detected in tissues, even 14 days after medication withdrawal. A 
major part of this residual radioactivity was non-extractable, presu-
mably covalently bound to cellular macromolecules (4). No information 
is available concerning the identity and toxicity of these residual 
metabolites, which hampers a proper evaluation of the potential risk 
for humans of edible tissues of animals treated with furazolidone. 
In general reduction of the nitro-group is a major metabolic pathway 
of nitrofurans, resulting in the formation of nitroso-and hydroxyl-
amino-derivatives as reactive intermediates responsible for inter-
action with biological macromolecules, and ultimately in a cyano-
derivative as stable endproduct of reductive metabolism (5). 
The cyano-derivative 3-(4-cyano-2-oxobutylidene amino)-2-oxazolidone 
of furazolidone has been described as an important metabolite in vivo 
in rats, rabbits and eels (6,7,8) and in model systems using rat liver 
fractions and E. coli (9,10,11). In swine however, formation of this 
cyano-derivative occurred to a minor extent indicating a species 
difference in metabolism of furazolidone (12). 
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We have studied into more detail the metabolic conversion of furazo-
lidone in swine liver microsomes in order to elucidate the biotrans-
formation pathway in the target animal and to identify intermediate(s) 
which may react with cellular protein. Furthermore possible reaction 
sites for the interaction between furazolidone and microsomal proteins 
are suggested. 
MATERIAL AND METHODS 
Chemicals. [^-^CJ-furazolidone was a gift of Norwich Eaton Pharmaceuticals 
Inc. Norwich, New York; it was labeled in the methylene groups of the 
oxazolidone moiety (specific activity: 605 uCi/mmol, radiochemical 
purity > 99% by TLC-toluene/acetic acid/acetone/water = 600:240:80:25 
by vol. and HPLC-conditions see below). 
Counting fluids: Minisolve (Zinsser Analytical (UK) LTD, Maidenhead) 
and Dimilume-30R (Packard Instrument BV, Delft) for aqueous and non-
aqueous samples, respectively. NAD(P)H, glucose-6-phosphate and 
glucose-6-phosphate dehydrogenase were obtained from Boehringer 
Mannheim GmbH, Mannheim, FRG. 
The deoxyribonucleosides and reduced glutathione (GSH) were purchased 
from Sigma Chemical Co. St. Louis, MO. The amino acids (Standard Kit 
22) were purchased from Pierce Chemical Company, Rockford Illinois, 
USA. All other chemicals used were of reagent grade. 
Preparation of microsomes. A liver of a 90 kg weighing female swine, 
with a known history without drug treatment, was perfused with a 1.15% 
KCl-solution, homogenized in a teflon Pbtter-Elvehjem homogenizer and 
centrifuged for 20 min at 9000 g. 
The supernatant (Sij-fraction) was centrifuged for 90 min at 105,000 g. 
After the supernatant (cytosolic fraction) had been decanted, the 
microsomal pellet was washed in 1.15% KC1 and then resuspended in 
100 mM-potassium phosphate buffer, pH 7.4. 
The Scj-fraction, cytosol and microsomes were all stored in liquid 
nitrogen. Protein concentration was determined by the method of 
Lowry et al. (13). 
Microsomal incubation. Unless stated otherwise, a standard incubation 
mixture was used containing 1 mM-NADPH, 3 mM-MgCl2, 0.1 M-potassium 
phosphate buffer, pH 7.4, 2.61 mg protein, 10 mM-glucose-6-phosphate 
and 10 U glucose-6-phosphate dehydrogenase. 
After a preincubation of 2 minutes, incubations were started by the 
addition of [l^C]-furazolidone dissolved in 50 ul of acetone (final 
concentration, 36.7 uM; corresponding to 44.4 x 10~3 uCi per 2 ml 
incubation mixture). The final volume was 2 ml. After standard 
incubation for 6 min at 37°C the reaction was terminated by the addi-
tion of 1 ml of acetone. Non-polar metabolites were extracted with 
4 x 2 ml of ethyl acetate. After evaporation of the ethyl acetate in 
a stream of nitrogen, the residue was dissolved in 300 ul of acetoni-
trile-water, 30:70, v/v (I; representing the ethyl acetate fraction) 
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and used for HPLC or radioactivity measurements. The HPLC-recovery 
of the ethyl acetate fraction was > 95%. After extraction with ethyl 
acetate, the protein in the aqueous phase was precipitated by the 
addition of ice-cold methanol. After centrifugation for 15 min at 
1500 g, the aqueous/methanolic supernatant was decanted and evaporated 
in a stream of nitrogen. The polar metabolites were dissolved in 300 yl 
of acetonitrile-water, 30:70, v/v (II; representing the aqueous frac-
tion) and were used for radioactivity measurements. The precipitated 
protein was washed three times with methanol, twice with ethanol and 
twice with diethyl ether. The resulting pellet (III; representing the 
protein fraction) was dissolved in 1 ml of soluene 350 (Packard 
Instrument BV) and used for measurement of the radioactivity (the 
amount of radioactivity defined as originating from covalently bound 
residues). After the protein was washed with methanol, no more 
radioactivity could be extracted. 
Anaerobic conditions were achieved by shaking the Incubation mixture 
for 3 min under a constant flow of argon, after which the incubation 
bottles were sealed. 
In studies on the effect of GSH, mercapto-ethanol, desoxyribonucleosi-
des and amino acids on the microsomal metabolism of furazolidone, 
these reagents were added to the incubation mixture at levels of 
5 mM or 10 mM. 
Incubations with microsomes inactivated by boiling for 3 min or 
without NADPH served as controls. Incubations and all other procedures 
before HPLC analysis were performed in the dark because of the photo-
sensitivity of furazolidone in solution (14). 
HPLC analysis. HPLC analyses were performed with a Waters 6000 A 
HPLC system. Separation of the non-polar metabolites of furazolidone 
and the mercapto-ethanol conjugate was achieved on a Chrompack Hyper-
sil 5 ODS column (250 x 4.6 mm). After injection of 100 yl of an incu-
bation sample, all radioactivity was eluted with a linear 22-min 
gradient of 2-100% acetonitrile in a mixture of water-1.0 M-sodium-
acetate buffer pH 5.0-acetonitrile (900:75:25, by vol.) at a flow rate 
of 1 ml/min. The eluent was monitored at 254 nm and for radioactivity 
measurements 0.2 ml fractions were collected. 
After addition of 3 ml of MInisolve, the amount of radioactivity was 
determined in a Philips liquid scintillation counter (type PW 4700). 
Counting efficiency was calculated by means of an external standard 
counting procedure. Data presented in this paper are mean values of 
at least three experiments. The experimental variation was within 
10 percent. 
HPLC-analysis of the aqueous phase after incubation in the absence or 
presence of glutathione was performed on a Hamilton PRP-1 column using 
a 22 min gradient of 2-99% acetonitrile in a 5 mM ammonia formate 
buffer, pH 3.6, at a flow rate of 1 ml/min (curve 7) . The protein was 
separated by ultrafiltration (Amicon Centrifree Micropartition System). 
The eluent was monitored at 254 nm and for radioactivity measurements 
0.2 ml fractions were collected. 
Identification of non-polar metabolites and a mercapto-ethanol con-
jugate. For identification of a mercapto-ethanol conjugate of fura-
zolidone, aliquots of fraction I (see earlier) were chromatographed on 
a semi-preparative Hibar prepacked column 250 mm x 10 mm Lichrosorb 
RP-18 (7 um) using a linear 22-min gradient of 2-100% acetonitrile in 
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a mixture of water - 1.0 M sodium acetate buffer pH 5.0 - acetonitrile 
(900:75:25, by vol.) at a flow rate of 4 ml/min. The eluent was moni-
tored at 254 nm. 
The fractions containing a mercapto-ethanol conjugate were collected 
and after evaporation to dryness under vacuum and redissolving in 
acetonitrile/water (20/80) the conjugate was chromatographed isocra-
tically on the same column (acetonitrile/water:20/80). Fractions con-
taining the mercapto-ethanol conjugate of furazolidone were collected 
and after gentle evaporation of the solvent under nitrogen used for 
identification. 
Ultraviolet (UV) absorption spectra were obtained with a Hewlett-
Packard photodiode array detection system (detector 1040 A, diskdrive 
9121, computer 85B and plotter 7470A). Infrared (IR) spectra of the 
various compounds in 5 mg KBr were recorded on a Bruker IFS-85 instru-
ment with diffuse reflectance techniques. Proton nuclear magnetic 
resonance (NMR) spectra of metabolites dissolved in CDCI3 were 
obtained with a Bruker CXP-300. Mass spectra were obtained with an AEI 
MS 902 mass spectrometer coupled to a VG-ZAB console. 
RESULTS 
In vitro metabolism of furazolidone 
Conversion of furazolidone by swine liver microsomes was linear for 
at least 8 min under the standard conditions used. 
After a 6-min aerobic incubation, 53.6% of the furazolidone was con-
verted (2.55 nmol/mg protein/min) of which 27.4% was extractable in 
ethyl acetate and 61.1% in water, while 11.6% was covalently bound to 
protein (Table 1). Under anaerobic conditions the amount of converted 
furazolidone was approximately 25% higher (rate: 3.25 nmol/mg 
protein/min). No conversion of furazolidone was observed when the 
microsomes were inactivated by heating, when NADPH was absent from the 
incubation mixture or when NADH was used instead of NADPH, indicating 
that NADPH-dependent enzymes are involved in the metabolism of 
furazolidone by swine liver microsomes. Furthermore cytochrome P-450 
is not involved in this conversion of furazolidone as indicated by 
the fact that carbon monoxide caused only a slight decrease in total 
conversion on saturation of the incubation mixture. Similar results 
have been described for rat liver microsomes (10). The cytosolic 
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fraction of swine liver gives a very low conversion of furazolidone 
under aerobic conditions in the presence of NADPH (rate: 0.11 nmol/mg 
protein/min). HPLC-analysis of the ethyl acetate extracts revealed 
three major peaks (A, B and C) (figure 1). 
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Figure 1: HPLC-analysis of the ethyl acetate extract after microsomal 
metabolism of [^CJ-furazolidone under aerobic conditions 
without (a) and with (b) the addition of 5 mM mercapto-
ethanol to the incubation mixture. For structures of meta-
bolites B, C and M^ see figure 4. F = furazolidone. 
The metabolites B and C (10.5% and 6.4% of total metabolites formed 
respectively) were identified as 3-(4-cyano-2-oxobutylidene amino)-2-
oxazolldone and 2,3-dihydro-3-cyanomethyl-2-hydroxy-5-nitro-la,2-di-
(2-oxo-oxazolidin-3-yl)imino- methylfuro[2,3-b]furan, respectively 
which have also been identified previously (9,10,11). 
Peak A appeared with the solvent front indicating high polarity and 
was not further identified. 
Covalent binding of furazolidone to protein and the effect of gluta-
thione, mercapto-ethanol, deoxyribonucleosides and amino acids. 
Under standard aerobic conditions, conversion-dependent covalent 
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binding of furazolidone to microsomal protein amounted to 0.29 nmol/mg 
protein/min (11.6% of total metabolites). Covalent binding increased 
under anaerobic conditions (0.38 nmol/mg protein/min). Covalent 
binding of furazolidone to microsomal protein is higher after aerobic 
incubations with swine liver microsomes (0.29-0.38 nmol/mg protein/min) 
compared with rat liver microsomes (0.14 nmol/mg protein/min) (10). 
(Table 1). 
0% 50% 100% 
control 
glycine 
alanine 
valine 
leucine 
methionine 
phenylanaline 
proline 
serine 
threonine 
cysteine 
asparagine 
glutamine 
tyrosine 
tryptophane 
lustidme 
lysine 
arginine 
glutathione 
mercapto-ethanol 
adenosine 
guanosine 
cytidine 
thimidine 
Figure 2: Effect of 10 mM amino acids, glutathione, mercapto-ethanol 
and deoxyribonucleosides on protein binding of [l^CJ-fura-
zolidone during microsomal metabolism. For glutathione, 
guanosine and histldine the protein binding was corrected 
for a decrease of the total conversion (54.2%, 66.7% and 
68.8% respectively compared with the control). In all other 
experiments the total conversion was not influenced. The 
experimental variation was within 10 percent. 
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The influence of the addition of 10 mM glutathione (GSH), mercapto-
ethanol, amino acids and deoxyribonucleosides to the incubation mix-
ture on the covalent binding of furazolidone to microsomal protein is 
shown in figure 2. Substantial decreases were observed only in the 
case of S-H-group containing agents cysteine, GSH and mercapto-
ethanol, but not for the other compounds. In the case of methionine an 
increase could be observed. 
Identification of a mercapto-ethanol conjugate of furazolidone. 
From the above results it is clear that thiol groups may react with 
an intermediate formed from furazolidone. When GSH was added to the 
incubation mixture the total conversion decreased, a yet inexplicable 
observation also made in other experiments (10); an increase of the 
relative amount of radioactivity could be detected in the aqueous 
phase while the percentages radioactivity in the ethyl acetate extract 
and covalently bound to protein decreased (Table 2). Using [^HJ-GSH 
and [l^CJ-furazolidone, HPLC-analysis of the aqueous phase yielded a 
double labeled [3H]/[1Z,C] fraction in a ratio of 1:1 (retention time: 
13.4-14.5 min). 
However, since under the conditions used the fractionated material was 
unstable, identification was not possible. When 5 mM mercapto-ethanol 
was added to the incubation mixture, a decrease in the amount of 
radioactivity in the aqueous phase was found, as well as a decrease of 
the radioactivity covalently bound to protein (Table 2). This radioac-
tivity was accounted for by the increase in the ethyl acetate frac-
tion. HPLC-analysis of this fraction showed the disappearance of 
metabolite B and C, and revealed a new peak (Mx), stable for at least 
48 hours at room temperature and representing 45-51% of total metabo-
lites formed. The formation of two minor new peaks M2 and M3 could 
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Figure 3: NMR (a), MS (b) and IR (c) spectra of the mercapto-ethanol 
conjugate of furazolidone. 
IR spectrum in KBr (cm-1): 3399: hydroxyl-group, 2927: Cl^-stretching, 
2240: cyano-group, 1772: oxazolidone, C = 0, 1691: a,3-unsaturated, 
C = 0 stretching; 
H-NMR spectrum in CDCI3 (ppm): 7.08: singlet (1 H): CH imine group; 
4.64: triplet (2 H): CH2 oxazolidone ring; 4.27: triplet (1 H): 
CH open furan ring; 3.92: multiplet (4 H): CH2 oxazolidone ring, 
CH2 3-hydroxyethylmercaptogroup; 3.56: multiplet (2 H): CH2 open 
furan ring; 3.02: multiplet (2 H): CH2 hydroxyethylmercaptogroup. 
The triplet at 5 4.27 (1 H) is coupled with the multiplet at S 3.56 
(2 H). The multiplet at S3.92 (two CH2~groups) coupled with the 
multiplet at §3.02 (2 H) and with the triplet at 54.64 (2 H). 
These couplings were proved by using homo-decoupling experiments; 
Mass spectrum (m/z): 
- field desorption: 271 (molecular ion), 193 (fragment ion: M+-78 
(= mercapto-ethanol) 
UV spectrum, Xmax (nm) 272; 
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also be observed accounting for 4 and 8% of total metabolites formed 
respectively. Metabolites B and C had disappeared completely (Figure 1; 
Table 2). The compound M^ was isolated by preparative HPLC and its 
spectral characteristics are shown in Figure 3. 
On the basis of these spectral characteristics the product was tenta-
tively identified as 3-(4-cyano-3(or 4)-S-hydroxyethylmercapto-2-
oxobutylidene amino)-2-oxazolidone, a mercapto-ethanol conjugate of 
furazolidone. 
DISCUSSION 
Microsomal incubation of furazolidone results in the formation of two 
identified ethyl acetate extractable metabolites, in an appreciable 
amount of covalent binding and in the formation of yet unknown water-
soluble metabolites. Performing the incubations in.the presence of 
5 mM mercapto-ethanol results in the disappearence of these two meta-
bolites, in the disappearence of an appreciable amount of water-
soluble unidentified metabolites and in a decrease of covalently bound 
material. Addition of 10 mM mercapto-ethanol caused an almost complete 
inhibition of the covalent binding. All radioactivity could be 
accounted for by an increase in the ethyl acetate fraction. HPLC-
analysis revealed a new peak M]^, representing approximately 50% of 
total metabolites formed. This metabolite was shown to be a mercapto-
ethanol adduct of the open-chain acrylonitrile derivative of furazoli-
done (I, figure 4 ) , which is therefore the reactive intermediate from 
which the other products (B, C, M^ and at least part of the polar 
metabolites, see figure 4) are formed and which may be responsible for 
the interaction with microsomal protein. The NMR-spectrum did not give 
conclusive evidence on the position of the mercapto-ethanol moiety, 
but from the fact that metabolite C, the adduct with furazolidone 
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JUL 
furazolidone 
H
 x 0 
R= C=N-N-C^ 
" 0 
SCr^Cr^OH 
metabolite B 
NC HO' 
metabolite C 
Figure 4: Proposed metabolic pathway of furazolidone by swine liver 
microsomes (MSH = mercapto-ethanol). 
itself, also results in reaction at the 3 position, it can be inferred 
that the thiol will attack the same carbon atom (see figure 4) . It 
should be stressed that, if the 3-position is the point of attack, the 
reactive intermediate in the metabolism of furazolidone is the open-
chain acrylonitrile derivative and not the hydroxylamino derivative, 
since the latter would give adducts at the 2- or 4 positions (1-5-17). 
In earlier studies with the nitrofuran N-[4-(5-nitro-2-furyl)-2-thiazo-
lyl]-acetamide (18) and with aromatic amines and amides using GSH as 
trapping agent (19-25) it has been reported that the N-hydroxy or 
nitroso-derivatives are responsible for the interaction. Apparently 
this is not the case for furazolidone, using mercapto-ethanol as 
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trapping agent. However, since an appreciable amount of radioactivity 
in the aqueous phase and the identity of M2 and M3 are still unknown, 
it cannot be excluded that adducts and/or metabolites are also formed 
from the N-hydroxy or nitroso-derivatives. 
The site of alkylation on microsomal protein appears to be the thiol 
group of cysteine, because this is the only amino acid that causes 
inhibition of furazolidone protein binding. Such an effect has also 
been reported for the 5-nitro imidazole ronidazole (26). An increase 
of covalent binding to microsomal protein after addition of methionine 
to the incubation mixture has also been reported for acetaminophen (27). 
Studies aimed at the elucidation of the process of covalent binding 
of furazolidone to protein with special attention for the role of its 
open-chain acrylonitrile-derivative, are presently undertaken. 
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CHAPTER 7: Reversible interaction of a reactive intermediate derived 
from furazolidone with glutathione and protein 
Submitted. 
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Department of Toxicology, Bornsesteeg 45, 6708 PD Wageningen, 
The Netherlands 
2) Department of Toxicology, Agricultural University, De Dreijen 12, 
6703 BC Wageningen, The Netherlands 
ABSTRACT 
Swine liver microsomes convert the nitrofuran furazolidone into 
N-(4-cyano-2-oxo-3-butenylidene)-3-amino-2-oxazolidone, a reactive 
open-chain acrylonitrile derivative. This derivative may be trapped 
with such thiol-group containing agents as glutathione and mercapto-
ethanol. However, this reaction is reversible: e.g. adding an excess 
of mercapto-ethanol to an aqueous solution (pH 7.4) of the glutathione-
conjugate results in conversion of 43% of this compound into the 
mercapto-ethanol conjugate. In addition, when microsomal protein is 
added to the glutathione-conjugate or the mercapto-ethanol conjugate, 
36% and 44% respectively becomes covalently bound to the protein. The 
amount of this covalently bound radioactivity decreases again on 
prolonged incubation at 37°C (42% disappearance within 24 hours), 
suggesting that the acrylonitrile derivative also reacts reversibly 
with thiol groups of microsomal protein. Indeed an excess of mercapto-
ethanol could remove covalently bound radioactivity from microsomal 
protein resulting in the formation of the mercapto-ethanol conjugate. 
The reversibility of the reaction is dependent on pH, as is demonstrated 
for the mercapto-ethanol conjugate. Below pH 2 this conjugate is 
stable; optimal exchange to microsomal protein is found between pH 7 
and 10. At very high pH (> 11) no binding to protein is found, 
although the conjugate disappears rapidly. The mercapto-ethanol 
conjugate exhibits mutagenic activity in the Salmonella/microsome-test 
indicating that the acrylonitrile derivative of furazolidone also 
interacts with DNA. 
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INTRODUCTION 
Furazolidone (N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone) , is a 
drug widely used in veterinary practice as a therapeutic agent against 
gastro-intestinal infections (Brander and Pugh, 1971; Rossoff, 1974). 
Because of its mutagenic and carcinogenic properties, possible residues 
in meat have become a matter of interest (Food and Drug Administra-
tion, 1976; McCalla, 1983). When piglets were dosed orally with [14C] 
furazolidone, radioactivity at ug-equlvalents of parent compound per 
gram of tissue could be detected two weeks after the treatment, 
although furazolidone itself was not present in tissues 2 hours after 
the last administration. Up to 55% of radioactivity in tissues proved 
to be non-extractable (Vroomen et al., 1986), suggesting covalent 
binding of reactive intermediates to tissue macromolecules. 
For the risk-evaluation of the consumption of meat, information is 
necessary concerning the metabolism of furazolidone in swine and the 
nature of possible covalently binding metabolite(s)• In several spe-
cies and model systems nitroreduction has been reported as an impor-
tant metabolic pathway, with a cyano-derivative [3-(4-cyano-2-
oxobutylideneamino)-2-oxazolidone] as major endproduct (Tatsumi et al., 
1978, 1981, 1984; Nakabeppu and Tatsumi, 1984; Abraham et al., 1984; 
Vroomen et al, 1987). Although this cyano-derivative was shown to 
be only a minor metabolite of furazolidone in tissues of swine in vivo 
(Vroomen et al., in press b), in vitro using swine liver microsomes, 
nitroreduction was responsible for at least 50% of total metabolism. 
The reactive intermediate formed by nitroreduction was shown to be 
an acrylonitrile derivative of furazolidone by the identification of 
3-(4-cyano-3-3_hydroxyethyl-mercapto-2-oxobutylidene amino)-2-
oxazolidone, a conjugate with mercapto-ethanol which was used as 
trapping agent (Vroomen et al., in press a). 
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Using [^ H] glutathione and [^C] furazolidone, evidence was collected 
for the formation of a glutathione-conjugate of furazolidone. 
Both mercapto-ethanol and glutathione could inhibit the covalent 
binding of furazolidone to microsomal protein, which is therefore pre-
sumably mediated by the same reactive acrylonitrile-derivative. In 
the present study the stability of the conjugates is studied and the 
conjugation is found to be a reversible process. The structural 
identity of the glutathione conjugate is established and the covalent 
binding to protein is shown to be governed by the same rules as con-
jugate formation. 
MATERIALS AND METHODS 
Chemicals. [l^C] Furazolidone was a gift from Norwich Eaton Pharmaceu-
ticals Inc., Norwich, N.Y., U.S.A. It was labelled in the methylene 
groups of the oxazolidone moiety (specific activity 2.69 uCI/mg; 
radiochemical purity > 99% by TLC (toluene-acetic acid-acetone-water, 
600:240:80:25, by vol.) and HPLC. Glutathione [glycine-2-3H]-, was 
obtained from Du Pont (specific activity at time of use: 21.0 uC/mmol); 
radiochemical purity > 99% by TLC (n-butanol-acetic acid-water, 25:4:10 
by vol.) and HPLC (on a Bondapak Ci8 column using the mobile phase 
0.25 % acetic acid). 
Scintillation liquids: Minisolve (Zinsser Analytical (UK) LTD, Maidenhead) 
and Dimilume-30R (Packard Instrument BV, Delft) for aqueous and non-
aqueous samples, respectively. NADPH was obtained from Boehringer 
Mannheim GmbH, Mannheim, FRG. Glutathione (GSH) was purchased from 
Sigma Chemical Co. St. Louis, M0. All the other chemicals used were of 
reagent grade. 
Microsomal incubation, the preparation of swine liver microsomes has 
been described elsewhere (Vroomen et al., in press a). A standard 
incubation mixture was used containing 1 mM NADPH, 3 mM MgCl2, 0.1 M 
potassium phosphate buffer (KPi) pH 7.4 and 2.61 mg protein. After a 
preincubation of 2 minutes, incubations were started by the addition 
of [l^C]-furazolidone dissolved in 50 ul acetone (final concentration: 
36.7 uM). The final volume was 2 ml. After incubation of 6-8 minutes 
at 37 °C, non-polar metabolites were extracted with ice-cold ethyl ace-
tate ( 3 x 5 ml). The protein fraction of the aqueous phase was 
separated by ultrafiltration (Amicon Centrifree Micropartition System) 
at 4°C during 15 minutes at 6000 g. 
The ultrafiltrate was directly used for HPLC. In studies on the effect 
of mercapto-ethanol and GSH on the metabolism of furazolidone these 
reagents were added to the incubation mixture at a final concentration 
of 5 mM. Incubations and all other procedures before HPLC analysis 
were performed in the dark because of the photosensitivity of furazo-
lidone in solution (Kalim, 1985). 
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HPLC-analysis. HPLC analyses were performed with a Waters Associates 
6000A HPLC system- Separation of the polar metabolites of furazolidone 
and the glutathione-conjugate was achieved on a Hamilton PRP-1 column 
(250 x 4.6 mm int.diam.) using a 22 min.-gradient of 2-99% acetonitrile 
in a 5 mM ammonium formate buffer, pH 3.6 at a flow rate of 1 ml/min 
(concave gradient curve 7 ) . 
After extraction with ethyl acetate, evaporation to dryness under 
nitrogen and redissolving in acetonitrile/water (30/70 by vol.), 
the separation of the mercapto-ethanol conjugate of furazolidone was 
achieved on a Chrompack Hypersil 5 ODS column (250 x 4.6 mm int.diam.) 
using a linear 22 min.-gradient of 2-100% acetonitrile in a mixture of 
water - 1.0 M sodium acetate/acetic acid buffer pH 5.0 - acetonitrile 
(900:75:25, by vol.) at a flow rate of 1 ml/min. The eluents were 
monitored at 254 nm and for radioactivity measurement 0.2 ml fractions 
were collected. When the mercapto-ethanol conjugate was extracted from 
the eluent with ethyl acetate, evaporated to dryness under nitrogen 
and stored in the dark at -40°C, the compound was stable for at least 
1 month. 
Exchange studies. For studies on the exchange of the glutathione or 
mercapto-ethanol conjugates of furazolidone, reaction mixtures were 
worked up and chromatographed as described above. 
The fractions containing the radioactive glutathione- or mercapto-
ethanol conjugate were collected in a final 0.1 M KPi buffer pH 7.4 
containing 10 mM mercapto-ethanol or 10 uM - 10 mM glutathione respec-
tively (at room temperature). The initial conjugate concentrations 
were approximately 10 yM. 
For studies on the exchange to microsomal protein from the gluta-
thione- and mercapto-ethanol conjugate, 5.2-5.6 mg microsomal protein 
was added to 6.3 and 8.1 nmol of the respective conjugates in a volume 
of 2 ml 0.1 M KPi buffer pH 7.4. 
For studies on the effect of pH on the exchange of the reactive inter-
mediate from the mercapto-ethanol conjugate to microsomal protein 5.6 
mg microsomal protein were added to 5.7 nmol of the conjugate in a 
volume of 2 ml 0.1 M KPi buffer. Covalent binding was measured after 
1-50 hr at room temperature. Studies on the pH or time dependent 
stability of the mercapto-ethanol conjugate were also performed at 
room temperature. 
Covalent binding to protein. The protein was precipitated by the addi-
tion of ice-cold methanol. After centrifugation for 15 min at 1500 g 
at 4°C, decanting the aqueous/methanolic supernatant and redissolving 
the protein in 0.1 M KPi buffer pH 7.4, the protein was again precipi-
tated by the addition of ice-cold methanol. This procedure was 
repeated three times. Subsequently the precipitated protein was washed 
three times with methanol, twice with ethanol and twice with ether. 
The resulting pellet was dissolved in 1 ml of Soluene 350 (Packard 
Instrument B.V., Delft) and used for radioactivity-measurement (the 
amount of radioactivity defined as originating from covalently bound 
residues). 
U.V. spectra. Ultraviolet (UV) absorption spectra of GSH/mercapto-
ethanol-conjugates of furazolidone were obtained with a Hewlett-
Packard photodiode array detection system (detector 1040A, diskdrive 
9121, computer 85B and plotter 7470A). 
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Radioactivity measurements. Radioactivity was measured in a Philips 
liquid scintillation counter (type PW 4700). Counting efficiency was 
calculated by means of an external standard-counting procedure. 
Salmonella/microsome-test. The Salmonella/microsome test was carried 
out as described by Maron and Ames (1983) using strain TA 100. 
Furazolidone and the mercapto-ethanol conjugate were tested dissolved 
in DMSO in the absence of Sg-mix, using a preincubation of 1 hour. 
RESULTS 
1. Formation of a glutathione-conjugate derived from furazolidone 
10 20 
T I M E (fairj) 
Figure 1: HPLC-analysis of the ultrafiltered aqueous phase after 
microsomal incubation of [l-^CJ-furazolidone 
A) without the addition of glutathione (inj.vol.: 200 ul) 
B) with the addition of 5 mM glutathione, immediately after 
stopping the incubation (inj.vol.: 100 ul) 
C) with the addition of 5 mM glutathione, 2 hours after 
stopping the incubation (inj.vol.: 100 ul). 
Upon conversion of [^C]furazolidone by swine liver microsomes under 
aerobic conditions, HPLC-analysis of the ultrafiltered aqueous phase 
revealed at least five peaks (Figure la). When 5 mM glutathione was 
added to the incubation mixture, HPLC-analysis of the ultrafiltered 
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aqueous phase immediately after stopping the incubation showed that 
these peaks could not be detected and a new peak (G\) was observed: 
retention time: 13.5-14.5 min (Figure lb). This peak accounted for 
64.2% of total radioactivity in the ultrafiltered aqueous phase. 
Ultrafiltration of the aqueous phase at 4°C immediately after extrac-
tion with ice-cold ethyl acetate, proved to be an essential step for 
the stability of peak G^ (no change for at least 24 hours at 4°C). 
Previously, instability was reported when this procedure was omitted 
(Vroomen et al., in press a). The ultraviolet absorption maximum of 
peak G\ was 270 nm, indicating that the nitrofuran-ring was converted 
into an open-chain moiety (A m a x furazolidone: 366 nm, X m a x open-chain 
cyano-derivative: 268 nm). When the ultrafiltrate (pH 7.4) was incu-
bated at 37°C for several hours before HPLC-analysis, peak Gi disap-
peared slowly and a number of new peaks could be observed (Figure lc). 
Using [^HJglutathione and [^^C]furazolidone, it was shown that peak G;[ 
corresponded to a double labeled [3H]/[^^C] fraction (ratio 1:1) indi-
cating the formation of a labile glutathione-conjugate from furazoli-
done (results not shown; Vroomen et al., in press a). 
2. Exchange of furazolidone residues between thiol groups at pH 7.4 
A. Exchange from glutathione to mercapto-ethanol. After addition of 
the glutathione-conjugate t0 °-1 M KPi buffer pH 7.4 containing 10 mM 
mercapto-ethanol and the usual workup procedures (within 24 hours), 
HPLC-analysis (see materials and methods) revealed a peak with a 
retention time of 12.4-12.8 min, accounting for 43% of initial radio-
activity and co-eluting with the mercapto-ethanol conjugate formed from 
the open-chain acrylonitrile derivative of furazolidone (Ml) of which 
the structure has been elucidated previously (Vroomen et al., in press a). 
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After collection of this peak, evaporation to dryness under nitro-
gen and redissolving in acetonitrile/water (20/80, by vol.)> C n e frac-
tion was chromatographed isocratically on the same column (acetoni-
trile/water: 20/80, by vol.) with a retention time of 5.5-6.3 min, 
again co-elutlng with Mi. Furthermore, the ultraviolet absorption 
spectra was superimposable with Mi (Amax= 272 nm). The mercapto-
ethanol conjugate Mi can thus be formed from the glutathione-conjugate 
derived from furazolidone. 
Figure 2: HPLC-analysis of a compound formed from Mi after addition of 
glutathione, inj.vol.: 200 yl (A); Gi obtained from microso-
mal incubation in the presence of glutathione, inj.vol.: 
100 ul (B) and a combination of both compounds, inj.vol.: 
200 ul = 100 yl (A) combined with 100 ul (B)(C). 
For structures of Mi and Gi see Figure 5. 
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B. Exchange from mercapto-ethanol to glutathione. One hour after the 
addition of 10 mM GSH to the radiolabeled mercapto-ethanol conjugate 
Hi at pH 7.4, HPLC-analysis revealed a [l^CJ-labeled peak which co-
eluted with G± (Figures 2a, 2b, 2c) and accounted for 37.5% of total 
initial radioactivity. Residual unreacted Mi (retention time: 
17.7-19.0 min) was removed by ethyl acetate extraction. The dependency 
of the formation of G± from Mi on the glutathione concentration after 
an incubation period of 1 hour at room temperature and pH 7.4 is shown 
in Figure 3. Maximum exchange (approximately 35%) was observed at con-
centrations > 100 uM GSH. Approximately 50% of the mercapto-ethanol 
conjugate is converted in yet unknown substances. 
100%T 
50 % 
300 
fiM GSH 
Figure 3: Influence of the glutathione concentration on the exchange 
of the [l^CJacrylonitrile-derivative (i) from 10 yM of the 
[l^C]mercapto-ethanol conjugate (M^; -*- -*-) to glutathione 
resulting in the formation of the [l^CJglutathione-conjugate 
("It _ - _ _ - _ ) • Values expressed as percentages of the total 
radioactivity (= 10 uM Mi at t=0) in the mixture after an 
incubation of 1 h. 
For structures of I, Mi and Gi see figure 5. 
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C. Reversible exchange from glutathione or mercapto-ethanol to protein. 
When microsomal protein was added to the glutathione-conjugate (pH 7.4), 
0.44 nmol equivalents were covalently bound per mg of protein after an 
incubation period of 2 hours at 37°C. As shown in table 1 this amount 
of covalently bound material decreased after a prolonged incubation 
time (42% disappearance within 24 hours). 
Table 1: Percentage covalent binding of furazolidone residues to 
microsomal protein after addition of the protein to the 
mercapto-ethanolconjugate (Ml) or glutathione-conjugate (Gi) 
formed form [l^C] furazolidone. 
Substrate 
8.1 nmol Mi 
8.1 nmol Mi 
6.3 nmol Gi 
6 .3 nmol Gi 
6.3 nmol Gi 
6.3 nmol Gi 
6.3 nmol Gi 
Protein 
(mg) 
_ 
5.6 
-
5.2 
5.2 
5.2 
5.2 
Incubation time* 
(hours) 
2 
2 
2 
2 
8 
24 
50 
% covalent binding** 
to microsomal protein 
0 
40.4 
0 
39.2 
25.4 
22.6 
21.5 
* Incubations were performed in a total volume of 2 ml 0.1 M KP^ buffer 
pH 7.4, 37CC. For working procedures see Methods and Materials. 
** Data are the mean of 2 experiments. Experimental variation was within 
10%. 
In the case of the mercapto-ethanol conjugate covalent binding to 
microsomal protein could similarly be detected: 0.63 nmol equivalents 
per mg of protein. This reaction is reversible. After suspending 5 mg 
of microsomal protein (to which 2 nmol equivalents of radioactivity 
were covalently bound) in 2 ml 0.1 M KPi buffer (pH 7.4) containing 
10 mM mercapto-ethanol, followed by precipitation of the protein after 
1 hour at room temperature, HPLC-analysis of the supernatant showed 
that 69.5% of total radioactivity had become conjugated to mercapto-
ethanol. 
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3- pH dependency of the exchange reaction. In Figure 4 an experiment is 
depicted in which 5.7 nmol of the mercapto-ethanol conjugate was incu-
bated at room temperature with or without microsomal protein at dif-
ferent pH values. 
100%T 
50%--
Figure 4: pH dependency of the stability of the mercapto-ethanol con-
jugate Mi at room temperature 
a) percentage unchanged Mi after 1 hr 
b) percentage unchanged Mi after 24 hrs 
c) percentage of Mi covalently bound after incubation for 
1 hr, in the presence of 5.6 mg microsomal protein. 
For the structure of Mi see figure 5. 
At pH values lower than 2 the conjugate is stable and no protein 
binding occurs. At higher pH values progressively more of the con-
jugate Mi disappears (ti/2 at pH 4: 100 wk, ti/2 at pH 7.4: 3.7 hr), 
with a concominant increase in covalent binding to protein. Optimum 
conditions for protein binding are between pH 7 and 10. At higher pH 
values the amount of protein binding decreases drastically. Also the 
conjugate disappears rapidly at these high pH's. 
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4. Mutagenicity tests with Salmonella typhlmurlum TA 100. The mercapto-
ethanol conjugate M^ (unlabeled) was tested in the Salmonella/microsome 
assay (without any added metabolizing system) using a preincubation 
period of 1 hour. A strong positive response was found with a clear 
dose-response relationship (Table 2). 
Table 2: Mutagenic activity of the mercapto-ethanol conjugate (M^) of 
furazolidone in Salmonella typhimurium TA 100 without any added 
metabolizing system (n=3). 
Compound 
DM SO 
Mercapto-ethanol (ul) 
Furazolidone 
"1 
Ug/plate 
50 
0.1 
0.05 
0.5 
5.0 
revertants/plate 
mean * S.D. 
113 + 5 
111 + 7 
957 + 35 
107 + 15 
251 + 11 
1810 + 68 
DISCUSSION 
In earlier studies using swine liver microsomes it was shown that the 
non-polar compounds 3-(4-cyano-2-oxobutylidene-amino)-2-oxazolidone 
and 2,3 dihydro-3-cyano-methyl-2-hydroxyl-5-nitro-la,2-di(2-oxo-
oxazolidin-3-yl)iminomethyl-furo[2,3-b]furan (Figure 5, metabolites B 
and C) were minor metabolites formed via the open-chain acrylonitrile-
derivative of furazolidone (Figure 5, metabolite I). Most of the meta-
bolites formed (61%) could not be extracted with ethyl acetate 
(Vroomen et al., in press a). At least 5 polar metabolites were formed 
by swine liver microsomes. When glutathione was added to the incuba-
tion mixture, these metabolites as well as metabolites B and C disap-
peared in favour of a glutathione-conjugate of furazolidone (Gi), 
indicating that the polar metabolites were also formed via inter-
mediate I of furazolidone, which is also responsible for interaction 
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with glutathione. Addition of mercapto-ethanol to the glutathione-
conjugate of furazolidone resulted in the formation of 3-(4-cyano-3-
S-hydroxyethylmercapto-2-oxobutylidene amino)-2-oxazolidone (metabo-
lite M ^ ) , a conjugate previously identified as formed from the open-
chain acrylonitrile-derivative of furazolidone (Figure 5, metabolite 
I) with mercapto-ethanol (Vroomen et al., in press a). 
H ^ 0 
R=C=N-N-C 
X-SH=glutattiione(X=G) 
or 
mercapto-ethanol(X=M) 
/S-X 
+X-SH | f 
l?
 " ^ + furazolidone / * V ' N 0 2 
DNA ^ X o 
metabolite B 
polar metabolites netabolite C 
Figure 5: Proposed metabolic pathway of furazolidone by swine liver 
microsomes. 
Furthermore such a chemical exchange could also be observed when 
glutathione was added to Mi, resulting in the formation of the gluta-
thione conjugate G\ or when microsomal protein was added to the con-
jugates resulting in covalent binding to protein. Covalent binding can 
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thus be mediated by mercapto-ethanol- as well as glutathione-conjugates. 
Covalent binding to protein decreased on prolonged incubation at pH 
7.4, suggesting that at least part of the covalent binding of the 
acrylonitrile derivative (I) to thiol groups of microsomal protein is 
also reversible. 
Indeed, an excess of mercapto-ethanol could remove covalently bound 
radioactivity from microsomal protein resulting in the formation of 
the mercapto-ethanol conjugate. The stability of the conjugate as well 
as the extent of covalent binding observed are dependent on pH. In 
addition to covalent binding the mercapto-ethanol conjugate of furazo-
lidone also exhibits mutagenic activity in Salmonella typhimurium TA 
100, indicating that the released acrylonitrile derivative I can also 
interact with DNA. 
The open-chain acrylonitrile derivative (I) is clearly the central 
reactive intermediate in the metabolism of furazolidone. The behaviour 
of this intermediate in its reversible reaction with thiols is in 
agreement with the occurrence of Michael and "retro-Michael" reactions 
as found by others for the reaction between thiols and a,3-unsaturated 
ketones (Onkenhout et al, 1982; 1983). 
Due to the fact that conjugation can be followed by deconjugation at 
pH 7.4, glutathione may act as a carrier of the reactive acrylonitrile 
derivative I of furazolidone. Whether this phenomenon also occurs in 
the in vivo situation is unknown, but there are some indications. For 
example, dosing [^C] furazolidone orally to piglets during 10 days, 
results in interaction with DNA and in non-extrable radioactivity in 
all tissues to approximately the same extent (Vroomen et al., 1986). 
Perhaps in vivo glutathione conjugates are formed from furazolidone in 
the liver, excreted in the blood, and release reactive intermediates 
at other sites in the organism. 
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Recently an equilibrium of free reactive agents with the derived 
glutathione-conjugates has also been recognized in the case of allyl 
and benzyl isothiocyanate (Bruggeman et al., 1986). Furazolidone would 
thus constitute the second example where such an equilibrium plays a 
role in the toxic effects. Further studies are indicated to investi-
gate the occurrence of these processes in vivo for furazolidone, 
because a possible equilibrium reaction of reactive intermediates with 
thiol groups of tissue-protein may have far-reaching consequences for 
the risk-evaluation of the consumption of meat contaminated with cova-
lently bound furazolidone residues. 
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PART III CONCLUSIONS AND SUMMARY 
CHAPTER 8: Summary and concluding remarks 
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SUMMARY AND CONCLUDING REMARKS 
The experiments described in this thesis were undertaken to get a 
better understanding of the kinetics and biotransformation of the 
nitrofuran furazolidone upon oral administration to swine. Such 
information forms an essential prerequisite for making an appropriate 
assessment of the consumer hazards of edible products originating from 
animals treated with this compound. The experiments were conducted 
according to two different approaches: 
- kinetic studies in the target animal to determine the elimination 
kinetics of furazolidone and its metabolites from plasma and tissues 
upon oral administration of furazolidone 
- in vitro biotransformation studies using swine and rat liver 
microsomes to elucidate biotransformation routes and to identify 
reactive intermediates responsible for the interaction with 
biological macromolecules. 
Part I of this thesis starts with a description of some developments 
in animal husbandry during the last decades. This is followed by a 
review of literature data on physical/chemical and antimicrobial 
characteristics, toxicity, elimination kinetics and biotransformation 
of furazolidone (chapter 1). 
Part II of this thesis deals with the present study. In chapter 2 
a fast, sensitive method has been described for the determination 
of furazolidone in swine plasma, muscle, liver, kidney, fat and urine 
based on high-performance liquid chromatographic separation after 
solid-phase extraction on ExtrelutR 1. The sensitivity of the method 
was 1-2 ng/ml (g) for plasma and tissues and 25 ng/ml for urine. 
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From the kinetic studies the conclusion can be drawn that no accumu-
lation of furazolidone occurs in blood after oral administration of 
furazolidone to both piglets (chapter 3) and adult swine (chapter 4); 
the half life time was respectively 45 and 60 minutes. Furazolidone 
was rapidly and almost completely metabolized and urine proved to be 
the major excretion pathway of formed metabolites: 61% of the radio-
active dose administered to piglets had been exreted via the urine 
and 18% via faeces, while in urine of adult swine only traces of total 
dosed furazolidone could be recovered. In tissues of piglets and adult 
swine no residues of furazolidone could be detected at all. However, 
the experiments with piglets showed that relatively high levels of 
radioactivity were present in all tissues studied. After a withdrawal 
period of 14 days the concentrations varied from 0.9-4.3 ug-equivalents 
per gram tissue. Up to 56% of the radioactivity detected in organs and 
tissues appeared to be non-extractable and was partly associated with 
DNA. This may either be indicative for endogenous incorporation in 
physiologically occurring compounds or for covalent binding of reac-
tive intermediate metabolites of furazolidone to biological macro-
molecules (chapter 3 ) . 
Studies with the adult swine further revealed the formation of a 
cyano-derivative from furazolidone, namely 3-(4-cyano-2-oxobutylidene 
amino)-2-oxazolidone. In studies in other animal species, it was 
claimed that this cyano-derivative was a major metabolite in urine. 
However, this compound proved to be a minor metabolite in plasma 
(half life time: 4 hours) and tissues of adult swine. This may be 
explained by species differences in biotransformation of furazolidone, 
by a very fast elimination of the cyano-derivative via urine or by an 
effective trapping of reactive intermediate metabolites of furazolidone 
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by biological macromolecules or agents like glutathione (chapter 4 ) . 
Two major ethyl acetate extractable metabolites of furazolidone could 
be observed upon incubation in rat liver microsomes: the cyano-
derivative referred to before and a reaction product of furazolidone 
with its open-chain acrylonitrile derivative, namely 2,3-dihydro-3-
cyanomethyl-2-hydroxy-5-nitro-la,2-di-(2-oxo-oxazolidin-3-yl)imino-
methylfuro[2,3-b]furan. Approximately 2-7% of the totally formed 
metabolites proved to be covalently bound to microsomal protein. This 
covalent binding could be inhibited by addition of glutathione, which 
also resulted in an almost complete shift from non-polar to water-
soluble metabolites. No binding to DNA was detected when calf thymus 
DNA was added to a microsomal incubation mixture with furazolidone in 
contrast to the in vivo DNA interaction observed in the piglets. This 
may be explained by differences between the in vitro and in vivo 
situation in the availability of reactive intermediate metabolites of 
furazolidone for reaction with DNA (chapter 5 ) . 
The above mentioned ethyl acetate extractable metabolites of furazoli-
done proved to be only minor conversion products of furazolidone upon 
incubation in swine liver microsomes, while the percentage of the 
protein bound metabolites formed was much higher, namely 12-22%. The 
site of attack on microsomal protein is probably formed by the thiol-
group of cysteine as indicated by results of experiments performed 
with amino acids. 
Using mercapto-ethanol as a trapping agent for reactive intermediates, 
a new metabolite could be isolated upon incubation of furazolidone in 
swine liver microsomes. This compound was identified as a conjugation 
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product of the open-chain acrylonitrile derivative of furazolidone 
with mercapto-ethanol, namely 3-(4-cyano-3-3-hydroxyethyl-mercapto-
2-oxobutylidene amino)-2-oxazolidone. This conjugate accounted for 
approximately 50% of total amount of metabolites formed. In addition, 
neither the above mentioned ethyl acetate extractable metabolites nor 
covalent binding to microsomal protein could be observed when mercapto-
ethanol was added to the incubation mixture, indicating that the open-
chain acrylonitrile derivative plays a central role in reductive bio-
transformation of furazolidone by swine liver microsomes (chapter 6 ) . 
The open-chain acrylonitrile derivative of furazolidone binds rever-
sibly with thiolgroup containing agents such as glutathione and 
mercapto-ethanol or with microsomal protein. 
The reversibility of the exchange reaction is dependent on pH as is 
demonstrated for the mercapto-ethanol conjugate. Below pH 2 this con-
jugate is stable; optimal exchange to microsomal protein is found 
between pH 7 and 10. The mercapto-ethanol conjugate gives a distinct 
direct positive response in the Salmonella/microsome test using tester 
strain TA 100. This is probably due to an interaction of the acrylo-
nitrile moiety with DNA (chapter 7 ) . 
It can be concluded that furazolidone is rapidly and almost completely 
metabolized upon oral administration to piglets. A major part of the 
formed metabolites proved to be non-extractable from the tissues. 
It can not be excluded that these non-extractable metabolites are the 
result of covalent binding of a reactive intermediate metabolite of 
furazolidone to biological macromolecules such as protein or DNA. 
From in vitro studies using swine liver microsomes evidence has been 
obtained showing that the open-chain acrylonitrile derivative plays 
a central role in the biotransformation of furazolidone. 
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It has been shown that this reactive intermediate can bind reversibly 
to microsomal protein. Whether this non-enzymatic reaction also occurs 
in vivo is not yet known. As the possible presence of such covalently 
bound residues in edible tissues could have serious consequences for 
the acceptibility of the drug for massmedication of food producing 
animals, the identity of the non-extractable radioactive material in 
tissue of piglets should be further investigated, together with its 
bioavailability and toxicity. Efforts should also be made to identify 
the extractable radioactivity in tissues of piglets as only a small 
part of this fraction as so far has been identified. 
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CHAPTER 9: Samenvatting en slotbeschouwingen 
149 
SAMENVATTING EN SLOTBESCHOUWINGEN 
Dit onderzoek had tot doel meer inzicht te krijgen in de omzetting en 
verdwijning van furazolidon uit weefsels en organen van varkens na 
toediening via net voer. Dergelijke informatie is essentieel om op 
adequate wijze de risico's voor de consument te bepalen van eetbare 
delen afkomstig van dieren behandeld met dit geneesmiddel. Hierbij is 
gebruik gemaakt van twee verschillende benaderingen: 
- kinetische studies in het doeldier om de verdwijning van furazolidon 
en metabolieten uit plasma en weefsels te bepalen na orale toediening 
- in vitro studies in levermicrosomen van varkens en ratten met als 
doel biotransformatieroutes op te helderen en reactieve inter-
mediairen te identificeren die verantwoordelijk zijn voor de 
interactie met biologische macromoleculen. 
In deel I van dit proefschrift wordt allereerst de ontwikkeling in de 
intensieve veehouderij gedurende de laatste decennia beschreven. Dit 
wordt gevolgd door een overzicht van literatuurgegevens van furazoli-
don betreffende fysisch/chemisch en antimicrobisle eigenschappen, de 
toxiciteit, reslduen en het verdwijnen daarvan uit plasma, weefsels en 
organen en tenslotte de biotransformatie (hoofdstuk 1). 
In deel II worden in een 6-tal hoofdstukken de resultaten van het 
onderzoek beschreven. 
Hoofdstuk 2 beschrijft een snelle en gevoelige methode voor de bepa-
ling van furazolidon in plasma, urine, spier, lever, nier of vet van 
varkens gebaseerd op HPLC-scheiding na voorzuivering op een Extrelut-
kolom. De gevoeligheid van de methode werd bepaald op 1-2 ng/ml (g) 
voor plasma en weefsels en op 25 ng/ml voor urine. 
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Uit de resultaten van de kinetische studies kan geconcludeerd worden 
dat geen accumulatie plaats vindt van furazolidon in bloed van biggen 
(hoofdstuk 3) en volwassen varkens (hoofdstuk 4); de respectievelljke 
halfwaardetijden bedroegen 45 en 60 minuten. Furazolidon wordt snel en 
bijna volledig omgezet. De gevormde metabolieten blijken voornamelijk 
via de nieren te worden uitgescheiden: 61% van de totaal toegediende 
radioactlviteit aan jonge biggen werd uitgescheiden in de urine en 
18% in de faeces, terwijl in de urine van volwassen varkens slechts 
sporen van furazolidon konden worden aangetoond. In weefsels van zowel 
biggen als volwassen varkens konden geen residuen van furazolidon 
gemeten worden. 
De resultaten van de biggenstudie geven echter aan, dat wel radio-
actlviteit aantoonbaar was op relatief hoog niveau. Na een wacht-
periode van 14 dagen varieerden de gehalten in de verschillende 
weefsels tussen 0,9-4,3 ug-equivalenten per gram. Van de achterblij-
vende radioactlviteit bleek tot 56% niet extraheerbaar te zijn uit de 
organen en weefsels. Deze radioactlviteit was voor een gedeelte 
geassocieerd met DNA. Deze bevindingen kunnen een indicatie zijn voor 
of endogene incorporatie in fysiologisch voorkomende bestanddelen 6f 
covalente binding van reactieve intermediaire metabolieten aan biolo-
gische marcomoleculen (hoofdstuk 3). 
Studies met het volwassen varken toonden de vorming aan van een cyano-
metaboliet, namelijk 3-(4-cyano-2-oxobutylidene amino)-2-oxazolidone. 
In de literatuur wordt gesteld dat deze cyano-metaboliet een belang-
rijk omzettingsprodukt is in de urine van andere diersoorten. Deze 
stof blijkt echter van minder belang te zijn in plasma (half-
waardetijd: 4 uur) en weefsels van volwassen varkens. 
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Mogelljke verklaringen zouden kunnen zijn speciesverschillen in 
metabolisme van furazolidon, een zeer snelle eliminatie van de 
cyano-metaboliet via de nieren of het effectief wegvangen van reac-
tieve intermediaire metabolieten van furazolidon door biologische 
macromoleculen of stoffen zoals glutathion (hoofdstuk 4). 
Gebleken is dat microsomen uit de lever van ratten furazolidon omzet-
ten. Twee belangrijke, ethylacetaat extraheerbare metabolieten konden 
worden ge'identificeerd: de reeds eerder genoemde cyano-metaboliet en 
een reactieprodukt van furazolidon met zijn acrylonitrilderivaat 
namelijk 2,3-dihydro-3-cyanomethyl-2-hydroxy-5-nitro-la,2-di-(2-oxo-
oxazolidin-3-yl) iminomethylfuro [2,3-b]furan. Van de totaal gevormde 
hoeveelheid metabolieten werd 2-7% covalent gebonden aan microsomaal 
eiwit. De toevoeging van glutathion aan het incubatiemengsel vermin-
derde deze covalente binding en veroorzaakte tevens een bijna complete 
verschuiving van ethylacetaat extraheerbare metabolieten naar water-
oplosbare metabolieten. In tegenstelling tot de in vivo situatie bij 
jonge biggen werd geen binding aan DNA waargenomen, nadat thymus DNA 
afkomstig uit kalveren was toegevoegd aan een microsomaal incubatie-
mengsel met furazolidon. Dit kan wellicht verklaard worden door ver-
schillen tussen in vitro en in vivo betreffende de "toegankelijkheid" 
van het DNA voor reactieve verbindingen van furazolidon (hoofdstuk 5). 
De bovengenoemde met ethylacetaat extraheerbare metabolieten bleken 
slechts in mindere mate gevormd te worden in varkensmicrosomen terwijl 
de covalente binding aan microsomaal eiwit aanzienlijk hoger was: 
12-22% van totaal gevormde hoeveelheid metabolieten. De thiolgroep 
van cysteine is hoogstwaarschijnlijk verantwoordelijk voor de 
covalente binding aan microsomaal eiwit zoals blijkt uit studies uit-
gevoerd met aminozuren. 
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Na omzetting van furazolidon door varkenslever microsomen in aanwezig-
heid van mercapto-ethanol voor het wegvangen van reactieve inter-
mediairen, kon een nieuwe metaboliet word en ge'isoleerd. Deze stof werd 
ge'identif iceerd als een conjugatieprodukt van het acrylonitrllderivaat 
van furazolidon met mercapto-ethanol, namelijk 3-(4-cyano-3-B-hydroxy-
ethyl-mercapto-2-oxobutylidene amino)-2-oxazolidone. Dit conjugaat nam 
ongeveer 50% van totaal gevormde metabolieten voor haar rekening. 
Toevoeging van mercapto-ethanol aan het incubatiemengsel leidde er 
bovendien toe dat noch de bovengenoemde ethylacetaat extraheerbare 
metabolieten noch covalente binding aan microsomaal eiwit konden wor-
den waargenomen. Deze bevindingen duiden er op dat het acrylonitril 
derivaat een centrale rol speelt in biotransformatie van furazolidon 
door varkenslever microsomen (hoofdstuk 6). 
Er kon een reverslbele reactie worden waargenomen tussen het acrylo-
nitril derivaat van furazolidon enerzijds en glutathion, mercapto-
ethanol en microsomaal eiwit anderzijds. Het reversibel karakter van 
deze uitwisseling blijkt afhankelijk te zijn van de pH, zoals wordt 
aangetoond voor het mercapto-ethanol conjugaat. Beneden pH 2 is dit 
conjugaat stabiel; een optimale uitwisseling naar microsomaal eiwit 
vindt plaats tussen pH 7 en 10. Het mercapto-ethanol conjugaat ver-
oorzaakt een duidelijk direct positief effect in de Salmonella/micro-
soom test (stam TA 100), hoogstwaarschijnlijk veroorzaakt door een 
interactie van het acrylonitril gedeelte met DNA (hoofdstuk 7). 
Concluderend kan gesteld worden dat furazolidon na orale toediening 
aan biggen snel en bijna volledig omgezet wordt. Hierbij ontstaan 
produkten die voor een belangrijk deel niet extraheerbaar zijn ult 
weefsels. 
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Het kan niet uitgesloten worden dat deze niet extraheerbare metabo-
lieten het gevolg zijn van covalente binding van reactieve in-
termediaire omzettingsprodukten van furazolidon aan biologische 
macromoleculen zoals eiwit en DNA. Studies met varkenslever microsomen 
laten zien dat het acrylonitril derivaat een centrale rol speelt in de 
reductieve omzetting van furazolidon. Het is aangetoond dat dit 
reactief intermediair reversibel kan binden aan microsomaal eiwit. Of 
deze niet-enzymatische reactie ook plaats vindt in vivo is onbekend. 
Omdat de mogelijke aanwezigheld van dergelijke covalent gebonden resi-
duen in eetbare weefsels ernstige gevolgen kan hebben voor de aan-
nemelijkheid van dit geneesmiddel voor massamedicatie van voedsel-
producerende dieren, moet de identiteit van het niet-extraheerbare 
materiaal in weefsels van blggen verder onderzocht worden samen met de 
biologische beschikbaarheid en toxlclteit ervan. Ook moeten experimen-
ten gestart worden met als doel de extraheerbare radioactiviteit in 
weefsels van biggen te identificeren omdat slechts een klein gedeelte 
van deze fractie tot nu toe is opgehelderd. 
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